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ABSTRACT 
Equine Herpesvirus-1 (EHV-1) is an important ubiquitous enzootic equine pathogen and 
one of the most common respiratory pathogens of the horse, causing epidemic abortion, perinatal 
mortality, respiratory disease, occasionally neurological disease in horses, and significant 
economic losses to the horse industry. EHV-1 induces several clinical signs of disease ranging in 
severity, from mild respiratory distress to abortion in pregnant mares, neonatal foal death and 
neuropathogenic disorders. Protective immunity stimulated by natural EHV-1 infection is short 
lived and depends of both humoral and cellular immune responses. Vaccination remains today 
one of the best options to combat EHV-1 infection and several different strategies of vaccination 
have been investigated and developed over the past decades. The objective of this research was 
the design of a safe and effective virus-vectored vaccine to combat EHV-1 infections. EHV-1 
glycoprotein D (gD) gene was cloned into the Herpes Simplex Virus Type-1 (HSV-1) VC2 
vector, which contains the gK∆31-68 deletion and a deletion of UL20 amino-terminal 19 amino 
acids. The VC2 strain cannot infect axonal neurons of mice and rats and has been shown to 
produce protective immune responses against both HSV-1 and HSV-2 viruses in mice and 
guinea pig modes. Vaccination of mice with the HSV-VC2-EHV-gD increased virus neutralizing 
activities against EHV-1 (33.6%) in mice after three vaccinations, which was similar to 
commercial whole virus vaccine group (32.6%) and significantly higher than VC2 and 
Unvaccinated control groups (p<0.01 or p<0.001). Mice vaccinated with the VC2-EHV-gD 
group exhibited strong humoral and cellular immune responses detected by polychromatic flow 
cytometry significantly higher than other groups (p<0.01 or p<0.001). Induction of IgG1 and 
IgG2a antibodies were significantly higher in the VC2-EHV-gD group than other groups after 
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three vaccinations (p<0.001). It’s interesting that induction of IgM antibody in the Vetera group 
was significantly higher than other groups before and after challenge (p<0.01 or P<0.05). 
Vaccination with the VC2-EHV-gD also stimulated strong cellular immune response (IFN-γ and 
TNF). Additional studies are needed to assess the VC2-EHV-gD vaccine efficacy in generating 
protective humoral and cellular immune responses in horses. 
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CHAPTER 1: INTRODUCTION 
1.1 Statement of Problem 
Equine Herpesvirus-1 (EHV-1) is an important ubiquitous enzootic equine pathogen causing 
epidemic abortion, perinatal mortality, respiratory disease, occasionally neurological disease in 
horses, and significant economic losses to the horse industry. EHV-1 can infect many cell types 
in the respiratory tract, lymphoid organs and the nervous system. Cells can be infected by direct 
contact or by cell-to-cell contact with infected cells (R.  Paillot, Case, Ross, Newton, & Nugent, 
2008). Despite extensive vaccination protocols, EHV-1 continues to be a major cause of 
epidemic abortion, perinatal mortality, respiratory disease and occasionally neurological disease 
in horses.  
EHV-1can infect the respiratory tract, causing disease that varies in severity from sub-
clinical to severe and is characterized by fever, lethargy, anorexia, nasal discharge, and cough. 
Infection of the respiratory tract with EHV-1 typically first occurs in foals in the first weeks or 
months of life, but recurrent or recrudescent clinically apparent infections are seen in weanlings, 
yearlings, and young horses entering training, especially when horses from different sources are 
commingled (Figure 1.1). EHV-1 causes epidemic abortion in mares (Figure 1.2), the birth of 
weak nonviable foals, or a sporadic paralytic neurologic disease (equine herpesvirus 
myeloencephalopathy-EHM) secondary to vasculitis of the spinal cord and brain (B. Ahn, Zhang, 
Osterrieder, & O'Callaghan, 2011; Frampton et al., 2005; N. A. Fuentealba et al., 2014; S. Kim, 
Ahn, O'Callaghan, & Kim, 2012; Loregian et al., 2006; Pusterla & Hussey, 2014; Van de Walle, 
Peters, VanderVen, O'Callaghan, & Osterrieder, 2008; van Maanen, 2002; Walker, Ruitenberg, 
Love, & Millar Whalley, 2000).  
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Figure 1.1 Life cycle of EHV-1 
 
Figure 1.2 Prevalence of EHV-1 abortion 
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EHV-1 spreads via aerosolized secretions from infected coughing horses, by direct and 
indirect contact with nasal secretions, and contact with aborted fetuses, fetal fluids, and placentae 
associated with abortions (Damiani, de Vries, Reimers, Winkler, & Osterrieder, 2014). Like 
herpesviruses in other species, EHV-1establish latent infection in the majority of horses, which 
do not show clinical signs but may experience reactivation of infection and shedding of the virus 
when stressed (Damiani et al., 2014; Ma et al., 2012; Spiesschaert, Osterrieder, & Azab, 2015). 
Those epidemiologic factors seriously compromise efforts to control these diseases and explain 
why EHV-1 outbreaks can occur in closed populations of horses. Latency is a key element of 
EHV-1 biology as a survival strategy. Latency happens in 40-60% of adult horses. During 
latency, the expression of the EHV-1 genome is repressed and there are no clinical signs of 
diseases, virus shedding or cell associated viremia (B. Ahn et al., 2011; Bartels, Steinbach, Hahn, 
Ludwig, & Borchers, 1998; N. A. Fuentealba et al., 2014; Ma et al., 2012; R.  Paillot et al., 2008; 
Walker, Love, & Whalley, 1999). Also no infectious virus present unless latent virus has been 
reactivated. Latent virus can be reactivated by environmental stress. After reactivation, latent 
EHV-1 can be shed and infect susceptible horses. Reactivation of latent EHV-1 is likely to be 
one of the most important factors in precipitating outbreaks of neurological EHV-1 (Yeo, 
Osterrieder, & Stokol, 2013).  
Recently, a genetic variant of EHV-1 has been described, defined by a single point mutation 
in the DNA polymerase (DNApol) gene, that is more commonly associated with neurologic 
disease (Damiani et al., 2014; G. S. Hussey et al., 2013; Vandekerckhove et al., 2011). This 
mutation results in the presence of either aspartic acid (D) or an asparagine (N) residue at 
position 752.  Molecular diagnostic techniques can identify EHV-1 isolates carrying these 
genetic markers, although currently the implications of this finding for management of EHV-1 
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outbreaks, or individual horses actively or latently infected with these isolates, are uncertain. It is 
important to understand that both isolates can and do cause neurological disease, it is just more 
common for the D752 isolates to do so and it is estimated that 80-90% of neurological disease is 
caused by D752 isolates, and 10-20% by N752 isolates (B. C. Ahn, Kim, Zhang, Charvat, & 
O'Callaghan, 2011; G. P. Allen et al., 2008; Andoh et al., 2013; Lunn et al., 2009; Perkins, 
Goodman, Dubovi, Kim, & Osterrieder, 2008; "Proceedings of the Equine Herpesvirus-1 
Havermeyer Workshop. San Gimignano, Tuscany. June 2004," 2006; Slater et al., 2006). Experts 
do not currently advise any specific management procedures for horses based on which isolate 
they are latently infected with, and it is possible that 5-10% of all horses normally carry the 
D752 form (Ma, Lu, & Osterrieder, 2010). In the face of an active outbreak of EHV-1 disease, 
identification of a D752 isolate may be grounds for some increased concern about the risk of 
development of neurological disease (Goehring, Landolt, & Morley, 2010). 
Despite regular and widespread vaccination, outbreaks of EHV-1 continue to occur. In 
devastating recent outbreaks, an unusually high number of horses exhibited the neurological 
form of the disease, EHV-1 Myeloencephalopathy (EHM) (Burgess et al., 2012; Perkins, Van de 
Walle, Pusterla, Erb, & Osterrieder, 2013; Pronost, Cook, Fortier, Timoney, & Balasuriya, 2010; 
Pronost et al., 2012; Pusterla & Hussey, 2014; Traub-Dargatz et al., 2013). There is a growing 
concern in the U.S. horse industry over the increased number of neurologic cases of EHV-1 
reported in recent years, as well as the occurrence of several high-profile outbreaks. The Center 
for Emerging Issues, part of the Department of Agriculture's Animal and Plant Health Inspection 
Service, recently labeled the neurologic form of EHV-1 as a potentially emerging disease 
(USDA, 2007). 
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1.2 Prevention of diseases cause by EHV-1 
There is a pressing need for potent antiviral compounds to treat both disseminated as well as 
neurological forms of infections. EHV-1 infections are usually dealt with using management 
practices that limit spread of the disease, providing symptomatic relief to infected horses, 
including the use of steroids, non-steroidal anti-inflammatory agents, antibiotics for secondary 
bacterial infections as well as other compounds used to treat EHV-1-associated neurological 
symptoms like paresis, paralysis, distention of the urinary bladder, stiffness of pelvis or ocular 
damage, but no specific treatment is available (Perkins et al., 2009). The current antiviral 
treatments options are based on extrapolation from established regiments for nucleoside analogs 
such as acyclovir used for treatment of human infections with HSV-1 and VZV and have not 
been shown to change the outcome of EHV-1 infections significantly (Goehring, Landolt, et al., 
2010). There are no controlled studies reporting on the efficacy of the known antiherpetic agents 
in the treatment or prevention of EHM, nor describing their pharmacokinetics, bioavailability, 
and safety in horses. New therapeutic or virucidal agents could have great utility in slowing both 
the progression and spread of the disease in an epidemic situation (Gilkerson & Barrett, 2008). 
The use of vaccines in the prevention and control of infectious diseases in the horse is a 
widely accepted practice (Bannai et al., 2012; Bresgen, Lammer, Wagner, Osterrieder, & 
Damiani, 2012; Said et al., 2011a; Said, Lange, Beer, Damiani, & Osterrieder, 2013; Tsujimura 
et al., 2009a; Van de Walle et al., 2010). For many horses involved in competitive sport 
vaccination is mandatory and requires veterinary certification (Holmes et al., 2006).  
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Inactivated vaccines 
A variety of inactivated vaccines are available, including those licensed only for protection 
against respiratory disease, which currently all contain a low antigen load, and two that are 
licensed for protection against both respiratory disease and abortion which contain a high antigen 
load (Holmes et al., 2006; Newton, Geraghty, Castillo-Olivares, Cardwell, & Mumford, 2004). 
Performance of the inactivated low antigen load respiratory vaccines is variable, with some 
vaccines outperforming others. Performance of the inactivated high antigen load 
respiratory/abortion vaccines is superior than low antigen load, resulting in higher antibody 
responses and some evidence of cellular responses to vaccination (Colle, Tarbet, Grafton, 
Jennings, & O'Callaghan, 1996; Skinner & Davies, 2000). This factor may provide good reason 
to choose the high antigen load respiratory/abortion vaccines when the slightly higher cost is not 
a decision factor. 
Immunity following vaccination appears to be short-lived and it is recommended that foals 
and young horses be revaccinated at 6-month intervals. The benefit of intensive vaccination 
programs directed against EHV-1 and EHV-4 in foals and young horses is not clearly defined 
because, despite frequent vaccination, infection and clinical disease continue to occur. Horses 
having been naturally infected and recovered: Horses with a history of EHV infection and 
disease, including neurological disease, are likely to have immunity consequent to the infection 
that can be expected to last for 3 to 6 months (longer in older horses). Booster vaccination can be 
resumed 6 months after the disease occurrence (Holmes et al., 2006). 
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Modified live vaccine 
There is a single manufacturer providing a licensed modified live EHV-1 vaccine - 
Rhinomune (EHV-1) Equine Vaccine by Boehringer Ingelheim. It is indicated for the 
vaccination of healthy horses 3 months of age or older as an aid in preventing respiratory disease 
caused by EHV-1 (Rosas, Goodman, von Einem, & Osterrieder, 2006). 
All available vaccines make no label claim to prevent the myeloencephalitic form of EHV-1 
(EHM) infection. Vaccines may assist in limiting the spread of outbreaks of EHM by limiting 
nasal shedding EHV-1 and dissemination of infection. For this reason some experts hold the 
opinion that there may be an advantage to vaccinating in the face of an outbreak, but in advance 
of EHV-1 infection occurring in the group of horses to be vaccinated. The vaccines with the 
greatest ability to limit nasal shedding include the 2 high-antigen load, inactivated vaccines 
licensed for control of abortion (Pneumabort-K®: Pfizer; & Prodigy® Merck), a MLV vaccine 
(Rhinomune®, Boehringer Ingelheim Vetmedica) and an inactivated vaccine, (Calvenza®, 
Boehringer Ingelheim Vetmedica). 
Envelope glycoproteins of EHV-1 have been shown to play important roles in the entry of 
the virus into host cells. EHV-1 uses the same glycoproteins as other alpha herpesviruses (e.g. 
HSV, bovine herpes virus (BHV) and pseudorabies virus (PRV)) to bind to susceptible cells. 
Once the EHV-1 attached to the cells, the virus penetrates the cell by either fusion of the virus 
envelope with cell membrane or by endocytosis pathway. EHV-1 glycoproteins (gB, gC, and 
gD) are the most used antigen epitopes in vaccines. Many studies used various expression 
systems that include E. coli, Baculovirus, and plasmid DNA to test in animals as subunit 
vaccine such as gB, gC or gD (Foote et al., 2005; Foote, Love, Gilkerson, Wellington, & 
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Whalley, 2006; Walker et al., 2000; Weerasinghe et al., 2006). EHV-1 gD is required for virus 
entry and contains antibody epitopes, which elicit virus neutralizing antibody. Those antibodies 
will neutralizing extracellular viruses and reduce epithelial infection and virus shedding. 
Antibody response induced by EHV-1 gD subunit vaccine was similar to the response induced 
by inactivated whole EHV-1 vaccine (Foote et al, 2006). Injection with DNA vaccine encoding 
EHV-1 gD elicited both humoral and cell-mediated immune responses in a murine model of 
EHV-1 infection (Walid Azab & Osterriedera, 2011; Ruitenberg, Walker, Love, Wellington, & 
Whalley, 2000; Ruitenberg, Walker, Wellington, Love, & Whalley, 1999a, 1999b) .  
With live recombinant vector vaccines, viral antigens are expressed and synthesized inside 
of the infected cell, are presented via MHC class 1 (endogenous) and class II (exogenous) 
antigen-processing routes, and will stimulate both humoral and cell-mediated immune 
responses(Yeo et al., 2013).  
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CHAPTER 2: LITERATURE REVIEW 
2.1 Equine Herpesviruses 
Herpes is used to describe the chronic, latent and recurrent characteristics of infection 
induced by many herpesviruses. Microbiology, pathology, and immunology impacted veterinary 
medicine dramatically in the 1890s. William Wallace Dimock and Phil Edwards at the Kentucky 
Agriculture Experimental Station, Lexington found that the viral etiology of the epizootic 
abortion of mares was different from bacterial abortion in 1936 (Westerfield & Dimock, 1946). 
They described the gross pathological changes of aborted fetuses, including intra-nuclear 
inclusion bodies in the fetal lungs and livers, and gave clinical observations of viral abortions 
(Westerfield & Dimock, 1946). Later, Anderson and Goodpasture cultivated the equine abortion 
virus in laboratory animals and tissue culture (Anderson & Goodpasture, 1942), and a more 
extensive pathological findings were made by Westerfield and Dimock (Westerfield & Dimock, 
1946). In 1963, the virus was shown by electron microscopy to be a member of the herpes group 
(Plummer & Waterson, 1963). 
2.2 EHV-1 Taxonomy 
In the first International Committee on Taxonomy of Viruses (ICTV) report 
(International Committee on Nomenclature of Viruses. & Wildy, 1971), the genus Herpesvirus 
was established, consisting of 23 viruses and 4 groups of viruses named according to the usages 
of the day. In the second ICTV report (International Committee on Taxonomy of Viruses., 
Fenner, & International Committee on Nomenclature of Viruses., 1976), this genus was elevated 
to the family Herpetoviridae, which, presumably because of the misleading association of this 
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name with reptiles and amphibians, was renamed Herpesviridae in the third ICTV report 
(Matthews, 1979). Classification of herpesviruses continued and expanded. At the time of the 
third ICTV report (Matthews, 1979), the family Herpesviridae was divided into 3 subfamilies 
(Alphaherpesvirinae, Betaherpesvirinae and Gammaherpesvirinae) and 5 unnamed genera, and 
21 viruses were listed. A subsequent list compiled by the Study Group contained 89 viruses 
(Roizman et al., 1981). 
At the time of the seventh report (Minson et al., 2000) , the ICTV adopted the species 
concept, which recognizes that a virus and the species to which it belongs fall into different 
categories, the real and the conceptual (M. H. V. Van Regenmortel & Neurath, 1990). It reduced 
tensions concerning the pervasive use of a dual system for herpesvirus names, with the effect that 
the ICTV approach has been adopted for some (e.g. equine abortion virus is now well known as 
equid herpesvirus 1) and the ad hoc name for others (e.g. Kaposi's sarcoma-associated 
herpesvirus, rather than human herpesvirus 8). The rules for virus taxonomical names are that 
they are written in italics with the first letter capitalized, and never abbreviated. 
This naming system specified that each herpesvirus should be named after the taxon 
(family or subfamily) to which its primary natural host belongs. The subfamily name was used 
for viruses from members of the family Bovidae or from primates (the virus name ending with –
ine, e.g. bovine), and the host family name for other viruses (ending with –id, e.g. equid). Human 
herpesviruses were treated as an exception (i.e. human rather than hominid). Following the host-
derived term, the word herpesvirus was added, succeeded by an arabic number, which bore no 
implied meaning about the taxonomic or biological properties of the virus. Thus, the formal 
name of pseudorabies virus (also known as Aujeszky's disease virus) was established as suid 
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herpesvirus 1. Since herpesviruses had previously been named on an ad hoc basis, sometimes 
with the effect that a virus might have several names, the formal system promised a degree of 
clarity and simplicity to students and scientists in the research field. However, a number of 
practical disadvantages of the formal naming system emerged. Most importantly, many virus 
names (e.g. Epstein–Barr virus) were so widely accepted that they could not be dislodged (e.g. in 
this case by human herpesvirus 4). This led to the use of a dual nomenclature in the literature for 
some herpesviruses.  
 
The most recent update (2009) of herpesvirus taxonomy largely concerned the 
introduction of additional taxa to the family Alloherpesviridae. The current, complete list of 
Equid Herpesvirus taxa is given in the first column of Table 1. This table also provides the 
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common names and acronyms (abbreviations) of the viruses. The right-hand part of the table 
conveys genomic information (Table 2-1). 
Herpesviruses infect members of all groups of vertebrates and some invertebrates. 
Around 120 herpesviruses have been identified and isolated. The Herpesviridae family is divided 
into three lineages. The lineage of herpesviruses infecting mainly mammals and birds is 
subdivided into three groups or subfamilies – Alphaherpesvirinae, Betaherpesvirinae and 
Gammaherpesvirinae (α, β and γ) according to their tissue tropism, pathogenicity and behavior 
in tissue culture (Davison, 2002; McGeoch, Dolan, & Ralph, 2000). Nine equid herpesviruses 
have been identified (Table 2-1). Equine herpes virus-1 (EHV-1) to EHV-5 infect horses, EHV-6 
to EHV-8 infect donkeys and are also called asinine herpesvirus (AHV, AHV-1 to 3), and EHV-
9 or gazelle herpesvirus (GHV) infects Thomson’s gazelles (Ostlund, 1993; Taniguchi et al., 
2000).  
Alphaherpesvirinae subfamily is associated with variable host range, relatively short 
reproductive cycle, rapid spread in culture with efficient destruction of infected cells (cytolytic), 
and capacity to establish latent infections primarily, but not exclusively in the sensory ganglia, 
and therefore, significant primary and recurrent infection. The subfamily contains the genera 
Iltovirus, Mardivirus, Simplexvirus, and Varicellovirus (M. H. Van Regenmortel, 2000). 
Betaherpesvirinae is characterized by restricted host range, long reproductive cycle, and 
slow infectious cycle with cytomegalia in cell culture. The virus can be maintained in latent form 
in secretory glands, lymphoreticular cells, kidneys, and other tissues. The subfamily consists of 
the genera Cytomegalovirus, Muromegalovirus, and Roseolovirus (M. H. Van Regenmortel, 
2000). 
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Gammaherpesviruses infect T or B lymphocytes, produce no infectious progeny, and are 
implicated in neoplastic transformation of lymphocytes. The host range of members of 
Gammaherpesvirinae subfamily is limited to the taxonomic family or order of their natural host. 
Latent virus is frequently demonstrated in lymphoid tissues. Subfamily includes 
Lymphocryptovirus and Rhadinovirus (M. H. Van Regenmortel, 2000). 
2.3 EHV-1 Herpesvirus architecture 
EHV-1 has been studied in the laboratory for more than 50 years (Girard, Greig, & 
Mitchell, 1963; Reczko, Bohm, & Straub, 1965).  Properties of EHV-1 have been characterized 
either directly or by extrapolation of the findings with HSV-1, VZV, or of its closest relatives, 
PRV and BHV-1.  
The herpesvirus family consists of a group of viruses distinguished by the large size of 
their linear double-stranded DNA genomes (about 130 – 250 kbp) and a common architecture of 
infectious particles (Chiu & Rixon, 2002). The common features shared by these herpesviruses 
were the most important criteria for the classification of a herpesvirus before classification by 
molecular biology and genomic sequencing (Chowdhury, Kubin, & Ludwig, 1986). All 
herpesviruses identified to date, which include eight different types that are known to infect 
human, and more than 170 other viruses that are found in animals as well as in fish and 
amphibians (R.  Paillot et al., 2008). 
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Table 2.1 Equid Herpesviruses 
Taxon name Common name 
Acrony
m 
Subfa
mily 
Host Species Disease 
Strain 
name 
GenBank 
accession 
RefSeq 
accession 
Genome 
size (kb) 
Reference 
Equid 
herpesvirus 1 
Equine abortion virus EHV1 α2 
Equus 
caballus 
Respiratory, 
abortion, 
neurological 
Ab4 AY665713 NC_001491 150,224 
(Telford, Watson, 
McBride, & 
Davison, 1992) 
V592 AY464052  149,430 
(Nugent et al., 
2006) 
Equid 
herpesvirus 2 
Equine herpesvirus 2/ 
Equine 
cytomegalovirus 
EHV2 γ3 
Equus 
caballus 
NA 86/67 U20824 NC_001650 184,427 
(Telford, Watson, 
Aird, Perry, & 
Davison, 1995) 
Equid 
herpesvirus 3 
Equine coital 
exanthema virus 
EHV3 α 
Equus 
caballus 
Coital 
exanthema 
  
NC_024771.
1 
151,601 
(Sijmons et al., 
2014) 
Equid 
herpesvirus 4 
Equine 
rhinopneumonitis 
virus 
EHV4 α2 
Equus 
caballus 
Respiratory 
NS8056
7 
AF030027 NC_001844 145,597 
(Telford, Watson, 
Perry, Cullinane, & 
Davison, 1998) 
Equid 
herpesvirus 5 
Equine herpesvirus 5/ 
Equine 
cytomegalovirus 
EHV5 γ3 
Equus 
caballus 
NA      
Equid 
herpesvirus 6 
Asinine herpesvirus 1 EHV6 α Equus asinus 
Coital 
exanthema 
     
Equid 
herpesvirus 7 
Asinine herpesvirus 2 EHV7 γ3 Equus asinus NA      
Equid 
herpesvirus 8 
Asinine herpesvirus 3 EHV8 α Equus asinus Rhinitis Wh  NC_017826 149,332 
(Liu, Guo, Lu, 
Xiang, & Wang, 
2012) 
Equid 
herpesvirus 9 
Gazelle herpesvirus EHV9 α Equus asinus 
Gazelle & 
Equine 
neurological 
P19 AP010838 NC_011644 148,371 
(Fukushi, 
Yamaguchi, & 
Yamada, 2012) 
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EHV-1 genome was first reported in 1992 (Telford et al., 1992). EHV-1 is composed of 
an icosahedral nucleocapsid containing the viral genome, surrounded by an amorphous envelope, 
which contains several glycoproteins (Fig. 1). EHV-1 glycoproteins share extensive homology 
with human simplex virus (HSV), which is the prototype virus of the Alphaherpesvirinae 
subfamily. The entire linear double strand DNA genome of a plaque purified clone of EHV-1 
strain Ab4 has been sequenced (Telford et al., 1992). It is divided into a unique long (UL) and a 
unique short (US) region, both flanked by an inverted internal and terminal repeat sequence (IRS 
and TRS or IRL and TRL; respectively). The genome (150,223 bp) contains 80 open reading 
frames (ORFs), which encode 76 unique genes, four ORFs are duplicated in the TRS (Telford et 
al., 1992). 
Figure 2.1 Electron photomicrograph of EquineHherpesvirus Type 1(Gluck Equine Research 
Center). 
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gL, gM Viral DNA 
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Figure 2.2 Schematic of EHV-1 virion structure (R.  Paillot et al., 2008). Herpesvirus virion 
consists of a core containing a linear, double stranded DNA, an icosadeltahedral capsid, 
approximately 100-110 nm in diameter, comprised of 162 capsomeres with a fissure running 
down the long axis as well as an amorphous, sometime asymmetric material that surrounds the 
capsid, designated as the tegument, and an envelope containing viral glycoprotein spikes on its 
surface. 
2.3.1 Envelope, Tegument and Nucleocapsid 
EHV-1 virions are about 120-200 nm in diameter, slightly pleomorphic, spherical and are 
enveloped in a cell-derived biolipid membrane, which is very similar to Herpes Simplex Virus 
(HSV) (Figure 2-3) (Brown & Newcomb, 2011). A typical trilaminar appearance covers the 
outer of the virion (Epstein, 1962). The surfaces of the envelope are roughly 800 distinct spikes 
of viral glycoproteins dispersed over the entire surface (Abodeely, Lawson, & Randall, 1970; 
Abodeely, Palmer, Lawson, & Randall, 1971). The viral glycoproteins from the membrane 
contact with tegument proteins directly (Grunewald et al., 2003). At least 12 membrane proteins 
are present on the surface of the virion envelope (Roizman & Whitley, 2001). There are more 
than 1,000 of individual proteins per virion (Spear, 2004). 
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Table 2.2 Envelop Glycoproteins of EHV-1 
Glycoprotei
n 
Former Name 
EHV-1 
ORF 
HSV-1 Function 
gB gp14 33 UL27 
Cell penetration and cell-to-cell 
spreading 
gC gp13 16 UL44 Attachment and egress 
gD gp17/18 or gp60 72 US6 
Cell penetration and cell-to-cell 
spreading 
gE None 74 US8 Cell-to-cell spreading 
gG None 70 US4 Unclear 
gH None 39 UL22 Unclear 
gI None 73 US7 Cell-to-cell  spreading 
gK None 6 UL53 Cell-to-cell spreading and virus egress 
gL None 62 UL1 Unclear 
gM 
gp21/22a or 
gp45 52 UL10 
Cell penetration and cell-to-cell 
spreading 
gN None 10 UL49.5 Processing of gM 
gp2 gp300 71 US5 Unclear 
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These glycoproteins are the target for neutralizing antibodies and often used for the 
development of new anti-viral vaccines. Also, herpesvirus envelope proteins play essential roles 
in the initial stages of virus infection, i.e., virion attachment and penetration to select cell types 
(Roberts, Pfister, & Spear, 2003). 
The tegument is the amorphous proteins structures between the capsid and the envelope. 
Those protein structures are required during the viral early infection (Klupp, Fuchs, Granzow, 
Nixdorf, & Mettenleiter, 2002; Kopp, Klupp, Granzow, Fuchs, & Mettenleiter, 2002). The 
tegument of HSV-1 contains about 20 proteins, including VP1/2 (UL36), VP11/12 (UL46), 
VP13/14 (UL47), VP16 (UL48), VP22(UL49), ICP0, ICP4 (Machtiger et al., 1980; McNabb & 
Courtney, 1992; Newcomb et al., 1996), and the virion host shutoff protein (UL41) as well as the 
products of the genes US2, US3, US10, US11, UL11, UL13, UL14, UL16, UL17, UL21, UL37, 
UL51, and UL56 (Mettenleiter, 2002, 2004). 
In all herpesviruses, the capsid is icosahedral in shape, composed of 162 capsomers, 
and assembled in the infected cell nucleus (Brown & Newcomb, 2011). The morphology of 
herpesvirus capsid has been well studied in order to understand the dynamics of virus 
assembly (Perdue, Cohen, Kemp, Randall, & O'Callaghan, 1975). A thick- walled, spherical, 
~ 120 nm in diameter nucleocapsid is isometric and composed of 162 capsomers arranged in 
5:3:2 axis of symmetry, triangulation class T = 16 icosahedral symmetry (Horne, Waterson, 
Wildy, & Farnham, 1960; Wildy, Russell, & Horne, 1960). Twelve capsomers at the vertices 
are "pentons". The remainder 150 capsomers are hexons, 9.5x12.5 nm in longitudinal section 
with a channel of 4 nm in diameter running from the surface along their long axis (Horne & 
Wildy, 1963; Watson, Russell, & Wildy, 1963; Wildy & Horne, 1963). Hexons are located at 
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the edges and faces of the capsid and fall into three classes (P – peripentonal, E- edge, and C-
center), depending on their positions on the surface lattice (Steven et al., 1986). EHV-1 hexons 
are composed of six molecules of major capsid protein (hexamers of VP9 (148 kDa)) and six 
of VP26 (UL35, 12kDa), which occupy the top of each hexon (Newcomb & Brown, 1989). 
Eleven of the 12 pentons are pentamers of VP9, while the number 12 is a unique vertex, a 
portal, cylindrical structure composed of twelve UL6, and contains an axial channel through 
which DNA is introduced into the capsid. By further extrapolation from HSV-1, portal protein 
UL6 interacts with the DNA cleavage and packaging proteins (putative terminase subunits) 
UL15 and UL28.  
Herpesvirus capsid populations are highly uniform in shape, and this property has made 
them attractive for structural analysis particularly by cryo electron microscopy followed by three 
dimensional image reconstruction (Figure 2-4) (Brown & Newcomb, 2011; Capuano et al., 2014; 
Kreitler et al., 2012). Capsomers are connected in groups of three by 320 triplexes, heterotrimers 
formed from two copies of VP23 (34kDa) protein and a single copy of VP19c (50kDa) that lie 
above capsid floor (Okoye et al., 2006; Trus et al., 1996). Scaffolding protein UL26.5 
participates in capsid formation but thereafter is lost and is not found in the mature capsid or 
virion. EHV-1 capsids also contain several other proteins, including, VP19 (59 kDa, -360 
copies), VP23 (36 kDa, -660 copies), and VP26 (12 kDa, -1,300 copies) (Newcomb & Brown, 
1989). The number of polypeptide species contained in the virions generally varies from 35 to 45 
(Perdue et al., 1975). Virus capsid assembly is under the control of tightly regulated program that 
includes the involvement of viral scaffolding proteins and cellular chaperonins, maturational 
proteolysis, and conformational changes on an epic scale (Perdue et al., 1975).  
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Figure 2.3 Structures of the HSV-1 virion. 
(a) Electron micrograph showing a single HSV-1 virion in cross-section. Note the four 
concentric layers that constitute the virion. The virion diameter is ~210 nm. (b) CryoEM 
reconstruction of an HSV-1 capsid shown in surfaceshaded representation viewed along a face 
(3-fold axis). One of the capsid faces is illustrated in color with the hexons, pentons and 
triplexes shown in red, orange and blue, respectively. The capsid diameter is 125 nm. (c) View 
of the HSV-1 capsid with a single hexon and a single major capsid protein molecule extracted. 
Also shown are the VP5 upper domain whose structure was determined by X-ray 
crystallography, and an example of the bacteriophage capsid protein that docks into the major 
capsid protein floor domain. Alpha helix, coil and beta structure are indicated in blue, gray and 
yellow, respectively (Brown & Newcomb, 2011). 
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Figure 2.4 De-enveloped EHV-1 nucleocapsids after residual tegument has been removed during 
centrifugation (Vernon). 
2.3.2 The Core 
The double-stranded DNA genome is organized as regularly spaced (;26 Å for HSV-1) 
concentric layers inside the capsid (Figure 2-5 & 2-6) (Zhou, Chen, Jakana, Rixon, & Chiu, 
1999). This pattern suggests a spool model for DNA packaging, similar to those in dsDNA 
bacteriophages such as λ, T4, and P22 (Baker, Newcomb, Booy, Brown, & Steven, 1990). The 
bulk of the tegument is not icosahedrally ordered. However, a small portion appears as 
filamentous structures around the pentons, interacting extensively with the capsid (Zhou et al., 
1999). Their locations and interactions suggest possible roles for the tegument proteins in 
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regulating DNA transport through the penton channel and binding to cellular transport proteins 
during viral infection. DNA is densely coiled in a ―liquid crystalline arrangement (Booy et al., 
1991) with the ends of the proteinaceous fibers anchored to the underside of the capsid shell. 
Figure 2.5 EHV-1 cores exposed after disintegration of nucleocapsid shells. The cores consist of 
coiled strands with a "beaded" appearance (Vernon). 
Figure 2.6 EHV-1 core material, presumably nucleoprotein. The core on the left consists of a 
coiled strand with a "beaded" appearance. The other micrographs show short fragments of helical 
fibers remaining when cores are flattened on carbon support films during dehydration (Vernon). 
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2.3.3 EHV-1 Viral Genome 
EHV-1 has a double-stranded linear DNA genome of approximately 150 kbp (96x106 
Da), has a base composition of 56.67% G + C, and contains 80 open reading frames able to 
encode proteins for the production of progeny genomes and mRNAs (Hollingsworth et al., 2015; 
Huang, Ma, & Osterrieder, 2015; Soboll Hussey, Ashton, Quintana, Van de Walle, et al., 2014; 
Spiesschaert et al., 2015). All herpesvirus genomes have a unique long (UL) and a unique short 
(US) region, bounded by inverted repeats (Table 1-2). The EHV-1 genome is divided into 
segments of a long unique region, UL (112.9 kbp); an internal repeat, IRS (12.7 kbp); a unique 
short segment, US (11.9 kbp); and a terminal repeat, TRS (12.7 kbp) (Figure 2-3). In addition, 
UL is fanked by a short inverted repeat of 32 bp (TRL/IRL) (N. Fuentealba et al., 2014; Said & 
Osterrieder, 2014; Soboll Hussey, Ashton, Quintana, Van de Walle, et al., 2014; Tewari, Del 
Piero, Cieply, Feria, & Acland, 2013). An organization of TRL-UL-IRL-IRS-US-TRS is typical 
of an alphaherpesvirus. US is found in either possible orientation relative to the fixed UL 
segment (Cullinane, Rixon, & Davison, 1988). 
2.4 EHV-1 Glycoproteins 
EHV-1 glycoproteins share extensive homology with human simplex virus (HSV), which 
is the prototype virus of the Alphaherpesvirinae subfamily (Table 2-2). Viral glycoproteins play 
an important role during entry via fusion of the viral envelope with cellular membranes, 
intracellular virion morphogenesis and egress, cell-to-cell spread, and virus-induced cell fusion 
(Cheshenko et al., 2014; Frampton et al., 2005; Hasebe et al., 2009; Kurtz, Singletary, Kelly, & 
Frampton, 2010; Neubauer, Braun, Brandmuller, Kaaden, & Osterrieder, 1997; Sasaki, Kim, et 
al., 2011; Spear, 2004; Van de Walle et al., 2008). 
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Figure 2.7 Map of the EHV-1 genome. 
(A) General structure of the genome. UL: unique long coding region; US: unique short coding region; IR: internal repeats coding 
region; TR: terminal repeats coding region. (B) Alignment of the open reading frames in a physical map that is collinear with the 
genome. 
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The EHV-1 specifies at least 14 glycoproteins: gB/gp14, gC/gp13, gD, gE, gG, gH, gI, 
gK/UL4, gL, gM, gN, gp10, gp2, and gp21/22a, most of which share high homology to those of 
herpes simplex virus type 1 (HSV-1) as prototypic virus for studying the Alphaherpesvirinae 
subfamily (Alber, Killington, & Stokes, 2000; Andoh et al., 2015; W. Azab & Osterrieder, 2012; 
Brandler et al., 2012; Chouljenko, Iyer, Chowdhury, Kim, & Kousoulas, 2010; Dietz et al., 2000; 
Esumi et al., 1999; Flowers, Flowers, Jennings, & O'Callaghan, 1995; Foster, Alvarez, & 
Kousoulas, 2003; Foster, Melancon, Olivier, & Kousoulas, 2004; Fuchs et al., 2002; N. A. 
Fuentealba et al., 2014; Guggemoos, Just, & Neubauer, 2006; Jambunathan et al., 2014; S. K. 
Kim, Bowles, & O'Callaghan D, 1999; Kukreja et al., 1998; Learmonth, Love, Gilkerson, 
Wellington, & Whalley, 2003; Neubauer, Beer, Brandmuller, Kaaden, & Osterrieder, 1997; 
Neubauer, Braun, et al., 1997; Neubauer & Osterrieder, 2004; Osterrieder, 1999; Osterrieder et 
al., 1997; Osterrieder, Seyboldt, & Elbers, 2001; Rudolph, Seyboldt, Granzow, & Osterrieder, 
2002; Ruitenberg et al., 1999a; Sasaki, Hasebe, et al., 2011; Seyboldt, Granzow, & Osterrieder, 
2000; Stanfield et al., 2014; Thormann, Van de Walle, Azab, & Osterrieder, 2012; Tsujimura et 
al., 2009b; Van de Walle et al., 2008; von Einem et al., 2004; Weerasinghe et al., 2006; 
Wellington, Love, & Whalley, 1996; Y. Zhang, Smith, Jennings, & O'Callaghan, 2000). In 
addition to those glycoproteins similar to HSV-1, EHV-1 also possesses at least three unique 
glycoproteins, designated gp10, gp2, and gp21/22a (G. P. Allen & Coogle, 1988; G. P. Allen & 
Yeargan, 1987; Guo et al., 1990; Turtinen & Allen, 1982; Wellington, Allen, et al., 1996; 
Whittaker et al., 1991). The functions of several individual EHV-1 envelope proteins, such as gB, 
gC, gD, gE, and gM, have been analyzed in some detail (Rudolph et al., 2002; Seyboldt et al., 
2000) (Andoh et al., 2015; Mackenzie-Dyck, Kovacs-Nolan, Snider, Babiuk, & van Drunen 
Littel-van den Hurk, 2014; Spiesschaert et al., 2015). EHV-1 also encodes several non-
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glycosylated membrane associated proteins: UL20, ORF76/US9, ORF37/UL24, 17/UL43, and 
26/UL34. 
Viral glycoproteins have three parts: the external ectodomain, which interacts with the 
host; a transmembrane segment, typically a single alpha-helix, and the internal part, the 
endodomain. All known glycoproteins that are capable of membrane fusion are trimers for at 
least part of the infectious cycle. Viral glycoproteins are also key determinants of membrane-
associated events occurring during virion morphogenesis and egress from infected cells. 
2.4.1 Glycoprotein B 
Glycoprotein B (gB) is a type 1 transmembrane protein and represents a highly conserved 
class III fusion protein present in members of the Herpesviridae family. In members of the 
Alphaherpesvirinae, it is thought that gB mediates the virus entry process through membrane 
fusion after initial attachment of the virion via gC to cell surface glycosaminoglycans, binding of 
gD to its cognate receptor and activation of the heterodimeric gH-gL complex, which in turn 
primes gB for fusion. In HSV-1, gB has been shown to bind several cellular receptors to 
facilitate viral entry. HSV-1 gB can bind to the paired immunoglobulin-like type 2 receptor 
(PILRα) to trigger viral fusion in the presence of gD. In addition to PILRα, non-muscle myosin 
heavy chain IIA (NMMHCIIA; also known as myosin 9) and myelin-associated glycoprotein 
(MAG), a protein expressed in neuronal tissues, were also shown to interact with gB and 
facilitate HSV-1 entry although it has remained unclear whether specific gB-receptor interactions 
are critical for entry. 
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Crystal structures of HSV-1 and Epstein–Barr virus (EBV) demonstrated that gB has 
structural similarity with other viral fusion proteins (Figure 2-8), such as the G protein of 
vesicular stomatitis virus (VSV) and gp64 of baculovirus, and likely acts as the key herpesviral 
fusion protein that requires gH/gL as a fusion regulator. However, it is not fully understood how 
gB and gH/gL interact during viral fusion (Connolly, Jackson, Jardetzky, & Longnecker, 2011). 
Figure 2.8 Herpes simplex virus 1 (HSV-1) glycoprotein B (gB) (PDB ID 2GUM) (part a) and 
Epstein–Barr virus (EBV) gB (PDB ID 3FVC) (part b). 
Domain I contains hydrophobic fusion loops that insert into the target cell membrane. For 
crystallization, the hydrophobic residues in the EBV gB fusion loops were replaced with the 
corresponding residues from HSV-1 gB. The carboxy-terminal domain V packs against the 
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coiled-coil core formed by domain III and proceeds through to domain I, headed towards the 
transmembrane (TM) region. This creates a hairpin-like organization of the structure such that 
the fusion loops and TM domain lie at the same end of the trimer. The locations of insertion 
mutations that reduce virus–host cell fusion without preventing gB expression are noted 
(Connolly et al., 2011). 
EHV-1 gB was first described in 1985 as antigenically and structurally similar to HSV-1 
gB (Snowden, Kinchington, Powell, & Halliburton, 1985). Later, it was shown that, like gB of 
other alphaherpesviruses, EHV-1 gB is essential for viral growth and direct cell-to-cell spread. 
This was deduced from the fact that only single infected cells, but no viral plaques, were 
observed when EHV-1ΔgB was used to infect non-complementing cell lines. A strong indication 
for its role as a fusogen was also reported; when viral titers of a gB-deficient EHV-1 virus could 
partly be restored by adding polyethylene glycol to induce fusion. However, there is no data 
available on the function of EHV-4 gB, the close relative of EHV-1. EHV-1 enters equine 
epithelial cells via direct fusion at the plasma membrane, while EHV-4 does so via an endocytic 
pathway (Spiesschaert et al., 2015).  
2.4.2 Glycoprotein C 
Glycoprotein C, gp13, is a gamma-1 gene product, encoded by of ORF 16, a 2.8-kb 
mRNA (Andoh et al., 2015; W. Azab et al., 2010; Matsumura, Smith, & O'Callaghan, 1993). 
The protein has the characteristic features of a membrane-spanning protein: an N-terminal signal 
sequence, a hydrophobic membrane anchor region, a charged C-terminal cytoplasmic tail, and an 
exterior domain with nine potential N- glycosylation sites (G. P. Allen & Coogle, 1988). 
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For herpes simplex virus 1, pseudorabies virus, EHV-1 and EHV-4, gC homologues have 
been shown to mediate the binding to cell surface heparan sulfate (Osterrieder, 1999; Tewari et 
al., 1995). Moreover, gC can protect the virus from complement-mediated neutralization (W. 
Azab et al., 2010). 
EHV-1 glycoprotein C (gC)-producing cells adsorbed equine RBCs, and that the lysate of 
EHV-1 gC-expressing cells agglutinated equine RBCs. EHV-1 lacking gC did not show HA 
activity. HA activity was inhibited by monoclonal antibodies (MAbs) specific for gC, but not by 
antibodies directed against other glycoproteins. In addition, HA activity was not inhibited by the 
addition of heparin. EHV-1 gC can bind equine RBCs irrespective of heparin, in contrast to other 
herpesvirus gC proteins (Andoh et al., 2015). 
Glycoprotein C is an important virulence factor of alphaherpesviruses in vivo. Infection 
of mice with a EHV-1 mutant virus that lacked gC ORF does not cause EHV-1-related disease, 
while wild-type virus infected mice exhibit massivie body weight losses, high virus titers in the 
lungs, and viremia (Osterrieder, 1999). Amino acids 152 to 275 of EHV1 gC specifies one of 
EHV-1 type-specific epitope (Crabb & Studdert, 1995). Immunization of mice with EHV-1 gC 
shows accelerated clearance of EHV-1 by virus specific antibodies, high levels of virus 
neutralising antibodies, and by cell mediated immune responses from the respiratory tissues 
following intranasal challenge (Herold, Visalli, Susmarski, Brandt, & Spear, 1994; Tewari et al., 
1995). IgG2b is the predominant antibody isotype produced in BALB/c (H-2K(d)) mice against 
gC derived from EHV-1-infected cells, while equal amounts of IgG2a/2b are found in the serum 
of C3H mice (H-2K(k)), indicative of a T-helper(1) response (Alber et al., 2000; Stokes et al., 
1996). 
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2.4.3 Glycoprotein D 
EHV-1 glycoprotein D (gD) has 22% amino acid identity with HSV-1, and has similar 3-
D structure and function (Figure 2-9). 
EHV-1 induces respiratory infection, neurological disorders and abortion in horses. Most 
of the currently available attenuated or inactivated vaccines against this infection are 
administered intramuscularly and only provide partial protection against the respiratory disease. 
The present study examines the effect of intranasal immunization with recombinant EHV-1 gD 
in BALB/c mice followed by challenge with three different EHV-1 strains during early to mid-
pregnancy. This vaccination approach was evaluated by virus isolation, DNA detection by 
polymerase chain reaction, histopathology and immunohistochemical localization of antigen in 
the lung, placenta and uterus. Non-immunized mice showed clinical signs of infection, positive 
virus isolation from lungs and uteri, and abortion induced by one of the virus strains. 
Endometrial lesions developed in some of these animals that have been described previously 
only in horses. Immunized mice and their offspring had no viral infection or typical lesions. 
Intranasally administered gD therefore induced partial or complete protection against three 
different EHV-1 strains in BALB/c mice (N. A. Fuentealba et al., 2014). 
The endotheliotropism of EHV-1 leads to encephalomyelitis secondary to vasculitis and 
thrombosis in the infected horse central nervous system (CNS). To identify the host factors 
involved in EHV-1 infection of CNS endothelial cells, we performed functional cloning using an 
equine brain microvascular endothelial cell cDNA library. 
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Figure 2.9 Crystal structures of the HSV-1 gD protein in free and as a complex with nectin-1 
forms. 
(a) Crystal structure of gD in the absence of receptor. The Trp294 residue of the gD protein is 
shown as cyan sticks. (b) Complex crystal structure of the gD-HVEM interaction. HSV-1 gD is 
shown in purple, its N-terminal residues (aa 1 to 37) are shown in blue, and HVEM receptor is 
shown green. (c and d) Complex crystal structure of the gD–nectin-1 interaction reported 
previously. HSV-1 gD is shown in purple, its N-terminal residues (aa 1 to 37) are shown in blue, 
and the nectin-1 receptor is shown in green. N and C indicate the N-terminal and C-terminal ends 
of HSV-1 gD, respectively (Gopinath, Hayashi, & Kumar, 2012). 
Exogenous expression of equine major histocompatibility complex (MHC) class I heavy 
chain genes conferred susceptibility to EHV-1 infection in mouse NIH3T3 cells, which are not 
naturally susceptible to EHV-1 infection. Equine MHC class I molecules bound to EHV-1 
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glycoprotein D (gD), and both anti-gD antibodies and a soluble form of gD blocked viral entry 
into NIH3T3 cells stably expressing the equine MHC class I heavy chain gene (3T3-A68 cells). 
Treatment with an anti-equine MHC class I monoclonal antibody blocked EHV-1 entry into 3T3-
A68 cells, equine dermis (E. Dermal) cells and equine brain microvascular endothelial cells. In 
addition, inhibition of cell surface expression of MHC class I molecules in E. Dermal cells 
drastically reduced their susceptibility to EHV-1 infection. These results suggest that equine 
MHC class I is a functional gD receptor that plays a pivotal role in EHV-1 entry into equine cells 
(Sasaki, Hasebe, et al., 2011). 
2.4.4 Glycoprotein H/L 
Glycoprotein H is essential for EHV-1 replication, plays a role in cell-to-cell spread and 
significantly affects plaque size and growth kinetics (T. Gianni, Leoni, & Campadelli-Fiume, 
2013). Glycoprotein H does not resemble any known fusion protein. Instead, it may act as a 
fusion regulator (Atanasiu, Saw, Cohen, & Eisenberg, 2010; Avitabile, Forghieri, & Campadelli-
Fiume, 2007). The structural studies showed that gH has three distinct domains with the N-
terminal domain (domain H1) shown to bind to gL (Chesnokova, Nishimura, & Hutt-Fletcher, 
2009). It has long been known that, in the case of EBV and HSV, gL is required for correct 
folding, trafficking, and function of gH (Chesnokova et al., 2009; Tatiana Gianni, Salvioli, 
Chesnokova, Hutt-Fletcher, & Campadelli-Fiume, 2013). How gB and gH/gL function and 
interact during alphaherpesviral fusion is still not fully understood. Recent studies suggest that 
fusion is a stepwise process starting with gD binding to its cognate receptors, followed by 
activation of gH/gL to prime gB for fusion. 
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2.5 The reproductive cycle of EHV-1 
As with other alpha herpesviruses, EHV-1 can infect a large range of cell types in the 
respiratory tract, lymphoid organs and the nervous system. Cells are infected by direct contact 
with EHV-1 or by cell-to-cell contact with infected cells (Mahmoud et al., 2013). 
The reproductive cycle of EHV-1 includes several steps: (1) EHV-1 attaches the cells 
through Binding Receptors; (2) EHV-1 gets inside of cells through virus-to-cell membrane 
fusion; (3) virion transport to the nucleus; (4) viral inhibition of host protein synthesis; (5) viral 
genome replication; (6) capsid assembly and DNA packaging and (7) release of the virus (Figure 
2-10). EHV-1 infections in horses are established because of exposure to infectious virus by the 
respiratory route or by reactivation of latent virus elsewhere in the body (G. P. Allen et al., 2008). 
After inhalation, viral replication occurs in the epithelia of the upper respiratory tract, including 
turbinates, pharynx, soft palate and tracheal epithelium (Kydd, Smith, Hannant, Livesay, & 
Mumford, 1994). Then, EHV-1 penetrates the epithelial barrier and by infecting a wide range of 
cell types, including immune cells, moves into deeper tissues of the respiratory tract and the 
draining lymph nodes. Subsequently, viral replication occurs in lymph nodes from 12 hours post 
infection (Kydd et al., 1994). From 4 to 6 days post infection, the infected lymphocytes migrate 
from lymph nodes into the blood, resulting in a cell-associated viremia and infected peripheral 
blood mononuclear cells (PBMC) carrying EHV-1 spread throughout the body. Internal organs 
such as the uterus (causing abortion) and nervous system (causing equine herpesvirus 
myeloencephalopathy) are infected (G. P. Allen & Bryans, 1986). 
Envelope glycoproteins of EHV-1 have been shown to play key roles in the entry of the 
virus into host cells. EHV-1 uses the same glycoproteins as other alpha herpesviruses (e.g. HSV, 
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bovine herpes virus (BHV) and pseudorabies virus (PRV)) to bind to permissive cells. EHV-1 
gC binds to heparan sulphate-containing glycosaminoglycans on the cell surface (Alber et al., 
2000). Glycoproteins D and M (gD and gM) are required for virus entry (W. Azab & Osterrieder, 
2012; Foote, Raidal, Pecenpetelovska, Wellington, & Whalley, 2006; Mahmoud et al., 2013). 
Once attached, the virus penetrates the cell by either fusion of the virus envelope and cell 
membrane or by non-classical endocytosis/phagocytosis (Frampton et al., 2007; Frampton et al., 
2010), which releases the nucleocapsid and tegument proteins of EHV-1 into the cell (Fig. 2-7). 
Like for other herpesvirus, it is believed that most of the tegument proteins dissociate from the 
capsid, which associates with microtubules via dynein, a minus-end-directed motor protein. The 
capsid is therefore transported along microtubules to the microtubules organizing centre, near the 
nucleus. This mechanism of capsid transport is important in the infection of cells such as neurons, 
when the site of infection can be far from the nucleus. The nucleocapsid binds directly to the 
nucleopore complex (NPC) and the viral DNA is translocated into the nucleus while the 
nucleocapsid remains in the cytoplasm (Deres et al., 2003; Osterrieder, Neubauer, Brandmuller, 
Kaaden, & O'Callaghan, 1998). 
The transcription of the EHV-1 genome is sequentially ordered. The tegument VP16 
(HSV) homologue protein of EHV-1, brought into the cell by the virus, is a strong activator of 
immediate early (IE) gene expression (Chesters, Allsop, Purewal, & Edington, 1997). The IE 
protein is encoded by ORF 64 and synthesized by cellular RNA polymerase II (Gray, Baumann, 
Robertson, Caughman, et al., 1987; Gray, Baumann, Robertson, O'Callaghan, & Staczek, 1987). 
This gene is required for the transcription of the adjacent early and late genes (Chen, Garko-
Buczynski, Zhang, & O'Callaghan, 1999; Garko-Buczynski, Smith, Kim, & O'Callaghan, 1998). 
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Early genes encode the proteins involved in stimulating virus replication. Late genes encode the 
viral structural proteins (Fig. 2-10). 
Herpesvirus nucleocapsids are assembled in the nucleus near scaffolding proteins before 
viral DNA encapsidation. The nucleocapsid, surrounded by tegument proteins, leaves the nucleus 
after envelopment at the inner nuclear membrane that contains glycoproteins. Virus will lose the 
primary envelope when the virus is leased through the outer nuclear membrane. A second 
envelopment occurs at the cytoplasmic membranes (ER or exocytotic vesicles), which contain all 
the viral glycoproteins, before the migration of the mature virus through the secretory pathway 
(via the Golgi apparatus). The infectious virus can be released into the extracellular space 
(Meehan et al., 2009; Neubauer, Braun, et al., 1997; Spiesschaert et al., 2015; Wang et al., 2009) 
or infect other cells via virus-induced cell fusion. In vitro, gB is absolutely essential for direct 
cell-to-cell spread of virions (Chouljenko et al., 2010; Neubauer, Braun, et al., 1997) . EHV-1 gD, 
gB and gK are key glycoprotein that involved in cell membrane fusion. 
2.6 EHV-1 Propagation and Virus Disease 
EHV-1 is transmitted by direct contact or inhalation with infected horses. Spread of 
infection occurs by intracellular routes involving many cell types. 
2.6.1 Propagation 
Primary EHV-1 infection occurs at the respiratory epithelium, resulting in erosion of the 
upper respiratory mucosal surface and viral shedding for 10–14 days after infection, or even 
longer in EHM affected horses. Cellto-cell spread results in the presence of virus in respiratory 
tract lymph nodes within 24–48 hours after infection (Kydd et al., 1994). 
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Figure 2.10 The reproductive cycle of herpesvirus (R.  Paillot et al., 2008). 
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A leukocyte-associated viremia is then established, which is directly responsible for the 
delivery of EHV-1 to other tissues; the specific leukocyte subset(s) harboring EHV-1 remain 
poorly defined. The viremia can persist for at least 14 days, and is a prerequisite for EHM and 
abortion as it allows for transport of the virus to the vasculature of the pregnant uterus or the 
CNS where infection of endothelial cells occurs. This infection results in damage to the 
microvasculature of the CNS due to initiation of an inflammatory cascade, vasculitis, 
microthrombosis, and extravasation of mononuclear cells resulting in perivascular cuffing and 
local hemorrhage (Kydd et al., 1994). 
The spinal cord gray and white matter are most commonly affected, with the brainstem 
being infrequently affected. While viremia is a common sequel to EHV-1 infection, transfer of 
virus to the CNS endothelium and development of EHM is not; typically some 10% of infected 
horses develop neurological signs during EHM outbreaks (Goehring, van Winden, van Maanen, 
& Sloet van Oldruitenborgh-Oosterbaan, 2006). The typical result is disseminated ischemic 
necrosis of the spinal cord. In contrast, abortion outbreaks can have attack rates in excess of 50%, 
but the underlying pathogenesis is otherwise similar to that of EHM (Wood, Mumford, Mair, & 
Slater, 2007). Viremia precipitates infection of endothelial cells in the small arterioles in the 
glandular layer of the endometrium at the base of microcotyledons, leading to vasculitis, 
microcotyledonary infarction, perivascular cuffing, and transplacental spread of virus at the sites 
of vascular lesions and abortion (D. J. Smith, Hamblin, & Edington, 2001). Most commonly the 
fetus is virus positive; however, in some instances the virus can be restricted to the placenta (K. 
C. Smith et al., 2004). Uterine endothelial cells have an increased susceptibility to infection in 
late pregnancy consistent with the occurrence of abortion principally in the last trimester (K. C. 
Smith, Mumford, & Lakhani, 1996). 
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2.6.2 Virus Disease 
EHV-1 is the leading cause of respiratory tract, infectious abortion and neurological 
disease. 
The pathogenesis of EHV-1 infection is well described after experimental infection with 
the EHV-1 strain Ab4. In the absence of mucosal antibody, nasal and nasopharyngeal epithelial 
cells are infected with EHV-1 (Figure 2-11) (Kydd et al., 1994). Subsequent erosions, due to 
epithelial cell necrosis and an acute inflammatory response, occur during the first week after 
infection, resulting in infectious virus shedding. EHV-1 spreads quickly through the body. 
Leucocytes in adjacent lamina propria and endothelial cells of blood and lymphatic vessels are 
also infected due to a cell-to-cell spread of infectious virus from the respiratory epithelium. 
Progeny virus and viral antigens are detected in respiratory epithelium as soon as 12h post 
infection. Endothelium of local blood vessels is infected within 2-4 days of infection. 
Infection of pregnant mares with EHV-1 can induce late-gestation abortion, stillbirth, and 
weak neonatal foals (Reed & Toribio, 2004). EHV-1 reaches the reproductive tract via cell-
associated viremia or by latent virus reactivation (Gerstenberg, Allen, & Stewart, 1999). Mares 
can abort months or years after a primary infection that has led to latency (Li, Browning, 
Studdert, & Crabb, 1996). Chorionic gonadotrophin (CG), which is one of the major hormones 
released by the placenta during early pregnancy (one to three months), is able to reactivate latent 
EHV-1 in vitro, and the endometrium has higher levels of CG than other tissue (Y. Zhang et al., 
1998). 
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Figure 2.11 EHV-1 initially infects the epithelial cells of the upper respiratory tract (1). EHV-1 
replicates and is shed (2), disseminates through the respiratory tract (3) or reaches the respiratory 
lymph nodes were PBMC will be infected (4). Circulation of infected leucocytes (5) during cell-
associated viremia disseminates EHV-1 to distant site such as the central nervous system or the 
reproductive tract. MALT: mucosal associated lymphoid tissue; NALT: nasal associated 
lymphoid tissue (R.  Paillot et al., 2008). 
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CG is absent by 120 days of pregnancy, but abortions are rarely detected before 4 months 
gestation. EHV-1 infects endometrial endothelial cells inducing thrombosis and ischaemia in the 
microcotyledons of the placenta. These uterine pathologies lead to a premature separation of the 
placenta from the endometrium, with subsequent anoxic death of the foetus. EHV-1 can also be 
transferred to the foetus, inducing extensive multi-organ infection and a wide range of 
macroscopic and microscopic lesions. The mare’s subsequent reproductive efficiency is not 
affected by abortion induced by EHV-1 infection (Li et al., 1996). When infection occurs during 
late gestation, the foetus may be born alive. However, the deterioration of the foal is rapid and 
almost all foals die. Infected foals show severe respiratory distress that amplifies the risk of viral 
pneumonia or secondary bacterial infection, which lead to respiratory failure within a few days 
(Gerstenberg et al., 1999). No treatment has been shown to prevent the fatal outcome of foetal 
infection with EHV-1. 
Neurological signs of disease (myeloencephalitis), from a mild hind limb ataxia to 
quadraplegia, have been observed after EHV-1 infection (Divers, Timoney, Lewis, & Smith, 
1992). Neurological signs are potential clinical sequels to EHV-1 respiratory tract infection and 
usually appear one week after infection (Li et al., 1996). The cell-associated viremia brings 
EHV-1 to the vasculature of the central nervous system. Infection of endothelial cells can lead to 
vasculitis and thrombosis of small blood vessels in the brain or spinal cord. These lesions might 
be exacerbated by Immunopathological mechanisms involving immune complex deposits, 
activation of the complement cascade, activation of polymorphonuclear leucocytes releasing 
cytotoxic agents, lysosomal enzymes and free radicals, and cell-mediated immunity 
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2.7 EHV-1 Diagnostic testing 
Virus culture and isolation is considered the gold standard test for making a laboratory 
diagnosis of EHV-1 and should be attempted especially during epidemics of EHM, concurrently 
with rapid diagnostic testing (PCR), in order to retrospectively be able to biologically and 
molecularly characterize the virus isolate (Slater et al., 2006). Virus culture, isolation, and 
identification of EHV-1 from nasal or nasopharyngeal swabs or buffy coat samples is strongly 
supportive of a diagnosis of EHM in a horse with compatible clinical signs. The likelihood of 
detecting EHV-1 during outbreaks of disease can be increased by testing in-contact horses, 
especially during episodes of fever. 
While viral culture and positive identification can be accomplished in as little as 2–3 days 
in a laboratory when the sample contains a high viral load, the time required to run these tests 
can limit their clinical utility for outbreak management. PCR has become the diagnostic test of 
choice because of its high analytical sensitivity and specificity. Positive PCR results can be 
obtained when virus isolation is negative because of low viral load. PCR detection of EHV-1 can 
be routinely performed in respiratory secretions from a nasal or nasopharyngeal swab and in 
uncoagulated blood. In the index case, both nasal secretions and uncoagulated blood should be 
analyzed simultaneously, because the interpretation of the results from respiratory secretions and 
blood can help in assessing disease stage. For nasal samples, a recent study has shown that nasal 
swabs are more sensitive than nasopharyngeal swabs for EHV-1 detection (Pusterla & Mapes, 
2008). Details of suitable sources of sampling materials are provided at the AAEP’s website on 
infectious disease outbreak management.40 Many conventional PCR protocols (single or nested 
PCR) targeting specific genes of EHV-1 have been published in recent years for the molecular 
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detection of EHV-1 (Tewari et al., 2013). Although considerable progress has been made in 
developing PCR assays, the lack of protocol standardization between laboratories and the lack of 
standardized use of quality assurance controls remain an ongoing challenge. 
Consequent to the identification of the DNApol SNP (D752/N752), real-time PCR tests 
have been developed that can distinguish these 2 biovars, and testing is commercially available 
(G. P. Allen, 2007; Nugent et al., 2006). However, the interpretation of genotyping of field 
isolates needs care, as 15–24% of EHV-1 isolates from horses with confirmed EHM do not have 
the D752 marker (Ma et al., 2010). The detection of the D752 marker is most commonly made in 
horses suffering from EHM. Whether detection of the D752 marker in an EHV-1-infected horse 
when no cases of EHM have yet occurred leads to a prediction of an increased risk of developing 
EHM has yet to be determined, although the perception that such a finding increases risk does 
influence treatment decisions for some clinicians. Whatever the risk status is, it is important to 
remember that the absence of the D752 marker does not preclude the development of EHM. The 
detection of latent EHV-1 infection is likely of no clinical diagnostic significance in the great 
majority of instances, independent of the biovar identified. 
Serologic testing which demonstrates a 4-fold or greater increase in serum antibody titer, 
by serum-neutralizing (SN) or complement-fixation (CF) tests, on acute and convalescent 
samples collected 7–21 days apart provides presumptive evidence of EHV-1 infection (Bannai et 
al., 2013; Mcguire, Vanhoosi.Gl, & Henson, 1971). 
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2.8 Immunity to EHV-1 
EHV-1 is a persistent virus. The acute clinical signs resolve after a few weeks, but EHV-
1 establishes a persistent infection with chronic reactivations. First time EHV-1 infection 
induced a fully protective immunity against re-infection lasting 4 to 8 months (Trapp et al., 
2005), although some reports demonstrate shorter periods of immunity lasting <3 months. EHV-
1 invades the host mostly via mucosal epithelium. The equine lung surface has been estimated to 
total around 2000 m² compared to around 400 m² in humans. A strong mucosal immune response 
is needed to prevent EHV-1 infection before it invades into cells and tissue (Soboll Hussey, 
Ashton, Quintana, Lunn, et al., 2014). 
2.8.1 Innate Immunity 
Macrophages and lymphocytes are dominant in normal lungs. After EHV-1 infection, 
neutrophils recruits to the tissue inflammation caused by infection, so the percentage of 
neutrophils increases, macrophages and lymphocytes decreases in a few days (Kydd, Hannant, & 
Mumford, 1996). During the 3 weeks after EHV-1 infection, bronchoalveolar CD8+ T 
lymphocytes increase significantly and show a cytotoxic activity against EHV-1 infected cells. 
Edington et al has also detected Equine type 1 interferon (IFNα/β) in nasal secretions and serum 
of ponies during the first two weeks after experimental infection with EHV-1 (Edington, Bridges, 
& Griffiths, 1989). IFNα/β has variety of immune-modulatory activities and stimulates both 
innate (e.g. enhancement of natural killer activity) and adaptive immunity (e.g. promotion of Th1 
response). The secretion of such IFN correlated with the duration of EHV-1 shedding, which 
could be an indicator of EHV-1 replication and epithelium damage (Edington et al., 1989). 
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2.8.2 Adaptive Immunity 
Adaptive immune responses to EHV-1 are believed to be initiated in NALT (nasal 
associated lymphoid tissue) and MALT (mucosal associated lymphoid tissue). Kydd et al. 
detected EHV-1 and viral antigens in the retropharyngeal and bronchial lymph nodes as early as 
12h after infection with EHV-1 (Kydd et al., 1994). 
2.8.2.1 Humoral Immune Response 
In the horse, there are one IgD, one IgM, one IgA, one IgE and five IgG isotypes. IgG 
subclasses include IgGa, IgGb, IgGc, IgG (T) and IgG (B) and these have been investigated 
using mAbs specific to IgG subisotypes (Lunn et al., 2009; Lunn, Holmes, Schram, & Duffus, 
1995). EHV-1 specific IgA type is the primarily antibody in nasal secretions, while IgGa and 
IgGb are the main isotype responses in serum (Breathnach, Yeargan, Sheoran, & Allen, 2001; 
Breathnach, Yeargan, Timoney, & Allen, 2006). 
Complement fixing (CF) and virus neutralizing (VN) antibodies appear within 2 weeks 
after infection with EHV-1 and IgGa, IgGb, IgGc, IgG(T) and IgM antibody serotypes can be 
detected (Hannant et al., 1993; K. C. Smith et al., 1993). However, CF antibodies are short lived 
and do not last more than 3 months, whereas VN antibodies are more durable (>1 year). Virus 
specific IgA with virus neutralizing activity is dominated in the local mucosal humoral response. 
The mucosal humoral immune response reduced virus shedding induced by subsequent infection 
with EHV-1 a few weeks after the initial infection (Breathnach et al., 2001). EHV-1 specific 
immune responses also take place in the draining lymph nodes of the respiratory tract after EHV-
1 infected subepithelial cells, leucocytes, and spread in the host through the blood and lymphatic 
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vessels. The role of circulating antibodies is controversial. Some studies have reported that 
serum VN antibody did not correlate with either protection from infection or the level of virus 
shedding in nasal secretion (Patel et al., 2003). Others have shown that the presence of VN 
antibody prior to EHV-1 infection reduces the amount and duration of nasopharyngeal virus 
shedding (Hannant et al., 1993; Mumford, 1985). These antibodies do not have any effect with 
cell-associated viremia. 
2.8.2.2 Cytokine Responses 
Virus-specific cell-mediated responses are important components of immunity against 
herpesviruses. Many studies have been done on cytokine responses to EHV-1 infection by 
interferon gamma (IFNγ), interferon alpha (IFNα), interleukin-4 (IL-4), interleukin-10 (IL-10), 
tumor necrosis factor (TNF-α) (Soboll Hussey, Ashton, Quintana, Lunn, et al., 2014; Soboll 
Hussey, Ashton, Quintana, Van de Walle, et al., 2014; Wilsterman et al., 2011). IFNγ synthesis 
is one of the most widely used markers of cell mediated immunity (CMI) to measure responses 
to herpesviruses in humans and it has now been applied to horses (Nugent & Paillot, 2009; R.  
Paillot et al., 2008; R. Paillot et al., 2005; R. Paillot, Grimmett, Elton, & Daly, 2008). 
Breathnach et al. measure antigen-specific IFNγ synthesis by equine lymphocytes in order to 
compare post EHV-1 infection PBMC samples to pre-infection samples and  they found that 
EHV-1 stimulated PBMC collected 10 days post-infection induced a higher percentage of CD4+ 
and CD8+ IFNγ+ T lymphocyte subsets, suggesting that it may contribute to protective 
immunity to EHV-1 (Breathnach, Soboll, Suresh, & Lunn, 2005). The percentage of IFNγ+ cells 
increased with age (R. Paillot et al., 2005), or repeatedly infected with EHV-1 (Coombs et al., 
2006), or after vaccination with a vaccinia-virus construct coding for the EHV-1 Immediate 
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Early Gene (R. Paillot et al., 2006). This increase in antigen specific T cells may indicate that 
EHV-1 specific memory cells can be boosted after subsequent challenge infection or vaccination 
with appropriate antigens. 
After in vitro EHV-1 stimulation, the IFNγ+ cells were phenotyped and predominantly 
associated with CD8+ cells (R. Paillot et al., 2005; R. Paillot et al., 2007). IFNγ promotes CMI 
by increasing viral peptides presentation by APC and promoting the development of T helper 1 
(Th1) lymphocytes. IFNγ is a key factor in the development of a type-1 response involving 
cytotoxic T lymphocytes (CTL), which leads to the destruction of virus infected cells. 
2.8.2.3 Cellular Immune Responses 
The cellular immune response is necessary in controlling intracellular EHV-1 and 
reducing or eliminating the cell-associated viremia (Soboll et al., 2003; Soboll Hussey, Ashton, 
Quintana, Lunn, et al., 2014; Soboll Hussey, Ashton, Quintana, Van de Walle, et al., 2014). 
Proliferation of lymphocytes is commonly used as an indicator of immune status because 
proliferation usually precedes the development of effector functions. The CTL response is an 
essential part of the immune defense against EHV-1. EHV-1 becomes intracellular in lymph 
nodes within hours of contact with host cells, so the cell mediated immune response to EHV-1 in 
vivo is very important (Kydd, Davis-Poynter, et al., 2006; Kydd, Wattrang, & Hannant, 2003). 
2.9 EHV-1 Vaccination 
Vaccination is an important strategy to prevent EHV-1 infection, in combination with 
management measures. Whole inactivated EHV-1 vaccines have been the main type of 
commercially available vaccines (Redig et al., 2011), which provide variable levels of protection 
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against the disease (N. A. Fuentealba et al., 2014; Gonzalez-Medina & Newton, 2015; Rusli, Mat, 
& Harun, 2014; Soboll Hussey, Ashton, Quintana, Lunn, et al., 2014). However, new strategies 
of vaccination that aim to mimic more closely the stimulation of the immune system induced by 
EHV-1 have been investigated (Van de Walle et al., 2010). Current commercialized or 
experimental vaccination strategies can be divided into either inactivated or live vaccines. 
Inactivated vaccines contain killed whole virus, subunit proteins or DNA, and live vaccines 
include attenuated virus or living virus-based vector vaccines. 
2.9.1 Inactivated vaccines 
2.9.1.1 Inactivated whole vaccines 
The majority of commercially available vaccines are inactivated whole virus, whose 
advantage is the absence of pathogenicity. Inactivated whole virus (usually inactivated by 
formaldehyde or β-propriolactone) does not replicate and spread between horses. However, local 
tolerance, pyrexia from high antigenic load and incomplete inactivation might happen during the 
vaccination. Doll et al. evaluated the antigenicity of killed virus vaccines for Equine 
Rhinopneumonitis on 1959 (Doll, Bryans, & Mc, 1959). Today, inactivated whole EHV-1 
vaccines are widely applied worldwide, such as CALVENZA EHV by Boehringer Ingelheim, 
Fluvac Innovator EHV 4 In 1 - Single Dose, Pneumabort-K + 1b (EHV-1) Equine Vaccine, 
Prodigy (EHV-1) Equine Vaccine by Merck. There are different responses to the inactivated 
EHV-1 vaccine. Foote et al. has measured the seroconversion of 159 mares and 101 foals after 3 
vaccinations with an inactivated whole EHV-1/4 vaccine. Less than 30% of mares and 50% of 
foals had response to the vaccination (Foote, Love, Gilkerson, & Whalley, 2002).  Abortion 
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storms have been still reported even after an extensive use of inactivated virus vaccine in many 
countries (van Maanen, Willink, Smeenk, Brinkhof, & Terpstra, 2000). 
2.9.1.2 Sub-unit vaccines 
Subunit vaccines have been developed against EHV-1 infections. Subunit vaccines 
contain one or more pure or semi-pure antigens from pathogen or produced by baculovirus-
expression systems. So, the subunit has to be the proteins or glycoproteins that involved in 
immune response. EHV-1 glycoproteins are essential for cell receptor recognition and the entry 
into the host cells and are most used in those subunit vaccines. Immunization with gB, gC or gD 
produced virus neutralizing antibodies and increased EHV-1 clearance from the respiratory tract 
of mice after experimental infection (W. Azab & Osterrieder, 2012; Foote, Raidal, et al., 2006; 
Mahmoud et al., 2013). These subunit vaccines generally require strong adjuvants to stimulate an 
immune response. Cook et al. studied an experimental sub-unit vaccine containing glycoproteins 
gp2, gp10, gB, gC, gD and gM with the adjuvant Iscomatrix™. The result has been shown to 
induce a virus neutralizing antibody response and protect hamsters from a live EHV-1 challenge 
(R. F. Cook, O'Neill, Strachan, Sundquist, & Mumford, 1990). The subunit vaccine might be 
processed by exogenous and endogenous routes and stimulate both antibody and CMI responses 
(R.  Paillot et al., 2008). And the antibody response was similar to the response induced by 
inactivated whole EHV-1 vaccine. Vaccinated ponies by an EHV-1 gD vaccine mixed with the 
adjuvant Iscomatrix™ via the intramuscular route developed a mixed virus-specific antibody 
response (Foote et al., 2005). 
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2.9.1.3 DNA vaccine 
DNA plasmids expressing EHV-1 genes, encoding whole antigenic proteins or epitopes 
have been used as vaccines. These antigens are directly expressed in the target host cell, 
processed by both exogenous and endogenous antigen processing routes and ultimately to the 
stimulation of both humoral and cellular immune responses (Ruitenberg et al., 1999b). This 
approach is therefore advantageous compared with inactivated whole virus or sub-unit vaccines 
(Ruitenberg, Love, Gilkerson, Wellington, & Whalley, 2000). DNA vaccines can also be 
adjuvanted by the insertion of genes coding for costimulatory molecules (e.g. cytokines), which 
in theory allow a more controlled modulation of the immune response than the one induced by 
conventional adjuvants. DNA vaccines have good stability and can be stored for long-term 
storage (Ruitenberg, Walker, et al., 2000). 
A DNA vaccine encoding gD has been shown to elicit both humoral and cell-mediated 
immune responses after two intramuscular immunizations, and to reduce respiratory lesions, the 
amount and duration of virus shedding, and abortion induced by challenge infection (Ruitenberg 
et al., 1999a, 1999b; Walker et al., 2000). The protection was improved by modifying the 
scheme of vaccination and including a gD protein booster immunization (Ruitenberg, Walker, et 
al., 2000). However, cell-associated viremia was not affected by vaccination (Slater et al., 2006). 
DNA vaccination efficiently stimulates an EHV-1 specific antibody response in the horse but so 
far no cellular immune responses have been studied. 
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2.9.2 Live EHV-1 vaccines 
2.9.2.1 Live Attenuated Vaccines 
Live attenuated vaccines are vaccine prepared from living organisms (viruses or bacteria) 
that have been attenuated under laboratory conditions. These vaccines replicate in a vaccinated 
individual and produce an immune response, but usually cause mild or no disease. 
Immunization with a live attenuated virus closely mimics natural infection. Antigens are 
live and processed to the immune system via both exogenous and endogenous antigen 
presentation pathways. These vaccines are expected to stimulate an immune response similar to 
those induced by infection. The intranasal or intramuscular inoculation of a live 
attenuated/modified EHV-1 is an attractive approach for the vaccination against EHV-1. 
However, the risk of reversion to virulence remains a concern for this strategy of vaccination. 
Two principal types of EHV-1 mutants have been derived and used as live attenuated EHV-1 
vaccines, namely thymidine kinase negative (TK-) (Cornick et al., 1990) and temperature 
sensitive (Ts) mutants (M. L. Cook, Thompson, & Stevens, 1986). Interesting, thymidine kinase 
negative (TK-) mutant reduced the clinical signs after challenge infection but did not prevent 
cell-associated viremia (Slater, Gibson, & Field, 1993). However, temperature sensitive (Ts) 
mutant induced a partial but significant protection against clinical signs, virus shedding and cell-
associate viremia (Patel, Didlick, & Bateman, 2004; Patel et al., 2003) 
2.9.2.2 Vector-Based EHV-1 vaccine 
Live recombinant vector vaccines are constructed by inserting selected EHV-1 genes into 
live, infectious, but non-disease-causing viruses, which may have been genetically modified. 
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With virus-based vector vaccines, viral antigens are expressed and synthesized within the 
infected cell, so they are presented via MHC class I (endogenous) and class II (exogenous) 
antigen processing routes. The selected viral antigens will stimulate both humoral and cellular 
immune responses (Nicolson, Rafferty, Brawley, & Onions, 1994). 
Recombinant poxviruses have been widely used for vaccination (Garcia-Arriaza et al., 
2014; Minke et al., 2004; Ons et al., 2014). Poxviruses are genetically stable and allow the 
insertion of a large segment of foreign DNA coding for selected antigens. Recombinant 
poxviruses derived from vaccinia or avipoxvirus are commercially available and several 
recombinant canarypoxbased vaccines have been developed for the horse (Karaca et al., 2005; 
Minke et al., 2004). 
Guo et al. tested a poxvirus as a vaccine vector for EHV-1 proteins in rodents and the 
immunization of hamsters with recombinant vaccinia viruses (Copenhagen strain) expressing 
EHV-1 gB and gC elicited a virus neutralizing antibody response and protected the hamsters 
from a lethal EHV-1 challenge (Guo et al., 1989; Guo et al., 1990). A MVA-based vaccine 
coding for EHV-1 gC (priming) was evaluated in hamsters in combination with a DNA 
vaccination coding for the same protein (boost). This combination induced both humoral and 
cellular immune responses, including proliferation and CTL activity (Huemer, Strobl, & 
Nowotny, 2000; Huemer, Strobl, Shida, & Czerny, 2000) . 
Paillot et al. tested a recombinant poxvirus vector vaccine coding for the EHV-1 IE 
protein, a known CTL target protein in horses. Multiple immunizations with this vaccine 
increased CTL activity and EHV-1 specific IFNγ synthesis compared with unvaccinated or 
single-vaccinated groups. The proportion of CD8α- T cells synthesizing IFNγ increased in 
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multiple-vaccinated ponies than the unvaccinated pony. The results showed that vaccination with 
this vector-based vaccine coding for the EHV-1 IE protein stimulated CMI, but this immune 
response alone did not protect against challenge infection (R. Paillot et al., 2005). 
2.10 EHV-1 Treatment 
Antiviral drugs, and specifically virustatics, are of theoretic value for the treatment of 
EHV-1 and have demonstrated in vitro efficacy against EHV-1 (Patel et al., 2003). The 
thymidine kinase inhibitor acyclovir (9-[(2-hydroxyethoxy) methyl]-guanine) is a synthetic 
purine nucleoside analog that selectively inhibits the replication of herpesviruses.64 The drug is 
phosphorylated initially by herpesvirus viral thymidine kinase, followed by 2 other 
phosphorylations by host cell kinases. The triphosphate acyclovir compound binds to and 
inhibits the viral DNA polymerase for the formation of viral DNA. 
Another nucleoside analog, valacyclovir shows greater promise based on 
pharmacokinetic data, although the lack of generic formulations makes it expensive in some 
countries (Breathnach et al., 2005). Currently, the effects of timing of valacyclovir 
administration relative to the onset of EHV-1 infection or EHM development on treatment 
outcome are unknown. 
The treatment of horses with myeloencephalopathy involves empiric supportive care, 
including nursing and supportive care in cases of recumbency, maintenance of hydration and 
nutrition, and frequent bladder and rectal evacuation (Pusterla & Hussey, 2014). Nonsteroidal 
anti-inflammatory therapy is frequently used as an adjunctive therapy, although their capacity to 
affect the development of the lesions of EHM is unknown. Similarly, corticosteroids and more 
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recently immune-modulators are both used in EHM treatment, although the justification is 
theoretical, as no evidence based study has demonstrated efficacy of either drug class for EHM. 
Similarly, antiviral drugs are also unproven in terms of their value to treat EHM, although their 
theoretical appeal has led to their increasing use against a background of an improved 
understanding of their pharacodynamics (Pronost et al., 2012). 
Corticosteroids are immunosuppressive drugs and could aid in the control or prevention 
of the cellular response adjacent to infection of CNS endothelial cells, thereby potentially 
reducing vasculitis, thrombosis and the resultant neural injury (Pusterla et al., 2010). This 
theoretical benefit of corticosteroid treatment of EHM has never been demonstrated in a clinical 
setting. Possible outcomes could include a positive effect through reduction of hypersensitivity 
disease associated with infection, or a deleterious effect due to a reduced immunological control 
of EHV-1 infection. Given our poor understanding of their efficacy in treating EHM, the use of 
corticosteroids is currently reserved for EHM cases presenting in recumbency or with severe 
ataxia, in which the prognosis is guarded for survival (Pronost et al., 2010; Pusterla & Hussey, 
2014). 
In summary, there is currently limited scientific rationale for the use of immune-
modulators, and no evidence-based studies of the value of antiviral drugs in the prevention and 
treatment of EHV-1 infection. It is important that studies of antiviral drugs is needed to evaluate 
their value in the control of EHV-1 infection in both early and late phases of natural disease, and 
for the reduction of shedding of virus during outbreaks. 
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CHAPTER 3: CONSTRUCTION AND CHARACTERIZATION OF THE VIRUS-
VECTORED VC2-EHV-GD VACCINE 
3.1 Introduction 
EHV-1 is an important ubiquitous enzootic equine pathogen, causing epidemic abortion, 
perinatal mortality, respiratory disease, occasionally neurological disease in horses, and 
significant economic losses to the horse industry (Damiani et al., 2014). EHV-1 can infect many 
cell types in the respiratory tract, lymphoid organs and the nervous system. Cells can be infected 
by direct contact or by cell-to-cell contact with infected cells (R.  Paillot et al., 2008). 
EHV-1 displays a strong tropism for epithelial cells of the upper respiratory tract and affected 
horses may initially have fever, inappetence and nasal discharge but subclinical infections are 
common (Damiani et al., 2014). Subsequently, the virus spreads systematically via infected 
mononuclear cells and reaches the vasculature of the pregnant uterus or central nervous system. 
Once the virus has reached these organs, infection proceeds to endothelial cells and damages the 
microvasculature followed by thrombus formation and hypoxia, which results in abortion or 
neurological disease, commonly referred to as equine herpesvirus myeloencephalopathy (EHM) (G. 
P. Allen, Kydd, Slater, & Smith, 2004). 
Despite regular and widespread vaccination, outbreaks of EHV-1 continue to occur. In 
devastating recent outbreaks, an unusually high number of horses exhibited the neurological 
form of the disease, EHV-1 Myeloencephalopathy (EHM) (Burgess et al., 2012; Perkins et al., 
2013; Pronost et al., 2010; Pronost et al., 2012; Pusterla & Hussey, 2014; Traub-Dargatz et al., 
2013). There is a growing concern in the U.S. horse industry over the increased number of 
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neurologic cases of EHV-1 reported in recent years, as well as the occurrence of several high-
profile outbreaks. The Center for Emerging Issues, part of the Department of Agriculture's 
Animal and Plant Health Inspection Service, recently labeled the neurologic form of EHV-1 as a 
potentially emerging disease (USDA, 2007). 
EHV-1 disease is controlled primarily by vaccination that generally starts when animals are 
approximately 6 months (Bresgen et al., 2012; Van de Walle et al., 2010). Current 
commercialized or experimental vaccination strategies can be divided into either inactivated or 
live vaccines. Inactivated vaccines contain killed whole virus, subunit proteins or DNA, and live 
vaccines include attenuated virus or living virus-based vector vaccines. Whole inactivated EHV-1 
vaccines have been the main type of commercially available vaccines (N. A. Fuentealba et al., 
2014; Gonzalez-Medina & Newton, 2015; Rusli et al., 2014; Soboll Hussey, Ashton, Quintana, 
Lunn, et al., 2014), which provide variable levels of protection against the disease. However, 
local tolerance, pyrexia from high antigenic load and incomplete inactivation might happen 
during the vaccination. 
New strategies of vaccination that aim to mimic more closely the stimulation of the immune 
system induced by EHV-1 have been investigated (Bresgen et al., 2012; Said et al., 2011b; Said et 
al., 2013; Tsujimura et al., 2009a; Van de Walle et al., 2010).  Live recombinant vector vaccines 
are constructed by inserting selected EHV-1 genes into live, infectious, but non-disease-causing 
viruses, which may have been genetically modified. With virus-based vector vaccines, viral 
antigens are expressed and synthesized within the infected cell, so they are presented via MHC 
class I (endogenous) and class II (exogenous) antigen processing routes (Patel et al., 2003). The 
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selected viral antigens will stimulate both humoral and cellular immune responses (Hofmann-
Sieber et al., 2010; Nicolson et al., 1994; Van de Walle et al., 2010). 
Envelope glycoproteins of EHV-1 have been shown to play important roles in the entry of 
the virus into host cells. EHV-1 uses the same glycoproteins as other alpha herpesviruses (e.g. 
HSV, bovine herpes virus (BHV) and pseudorabies virus (PRV)) to bind to susceptible cells. 
Once the EHV-1 attached to the cells, the virus penetrates the cell by either fusion of the virus 
envelope with cell membrane or by endocytosis pathway. EHV-1 glycoproteins (gB, gC, and gD) 
are the most used antigen epitopes in vaccines. Many studies used various expression systems 
that include E. coli, Baculovirus, and plasmid DNA to test in animals as subunit vaccine such as 
gB, gC or gD (Foote et al., 2005; Foote, Love, et al., 2006; Walker et al., 2000; Weerasinghe et 
al., 2006). 
Guo et al. tested a poxvirus as a vaccine vector for EHV-1 proteins in rodents and the 
immunization of hamsters with recombinant vaccinia viruses (Copenhagen strain) expressing 
EHV-1 gB and gC elicited a virus neutralizing antibody response and protected the hamsters 
from a lethal EHV-1 challenge (Guo et al., 1989; Guo et al., 1990). A MVA-based vaccine 
coding for EHV-1 gC (priming) was evaluated in hamsters in combination with a DNA 
vaccination coding for the same protein (boost). This combination induced both humoral and 
cellular immune responses, including proliferation and CTL activity (Huemer, Strobl, & 
Nowotny, 2000; Huemer, Strobl, Shida, et al., 2000).  Paillot et al. tested a recombinant poxvirus 
vector vaccine coding for the EHV-1 IE protein, a known CTL target protein in horses. Multiple 
immunizations with this vaccine increased CTL activity and EHV-1 specific IFN-γ synthesis 
compared with unvaccinated or single-vaccinated groups. The proportion of CD8α- T cells 
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synthesizing IFN-γ increased in multiple-vaccinated ponies than the unvaccinated pony. The 
results showed that vaccination with this vector-based vaccine coding for the EHV-1 IE protein 
stimulated CMI, but this immune response alone did not protect against challenge infection (R. 
Paillot et al., 2005). 
The envelope glycoprotein D of EHV-1 (EHV-1 gD) is essential for virus infectivity and 
functions in entry of virus into cells (Csellner et al., 2000; Whittaker et al., 1992). Glycoprotein 
D is one of the most potent inducers of virus-neutralizing antibody among the spectrum of EHV-
1 proteins (N. A. Fuentealba et al., 2014; Ruitenberg et al., 1999a; P. Zhang, Xie, Balliet, 
Casimiro, & Yao, 2014). Those virus neutralizing antibodies neutralize extracellular viruses and 
reduce epithelial infection and virus shedding. Monoclonal antibodies against EHV-1 gD 
provided passive protection against EHV-1 infection in a hamster model (Stokes, Allen, Pullen, 
& Murray, 1989), and gD is a prime candidate as a component of subunit vaccines against EHV-
1 in mouse models (Akhrameyeva, Zhang, Sugiyama, Behar, & Yao, 2011; N. A. Fuentealba et 
al., 2014; Tewari, Whalley, Love, & Field, 1994; Walker et al., 2000; Weerasinghe et al., 2006). 
EHV-1 gD have used eukaryotic expression systems which allow for glycosylation, processing 
and folding that are likely to mimic those of natural infection. Full-length EHV-1 gD expressed 
by a recombinant baculovirus (Bac gD) produced neutralizing antibody and both CD4+ and 
CD8+ T-cells in a mouse respiratory model (Tewari et al., 1994). A truncated form of EHV-1 gD 
expressed in insect cells generated protective responses associated with neutralizing antibody 
(Stokes, Cameron, Marshall, & Killington, 1997). Injection of EHV-1 gD DNA expressed by a 
mammalian expression vector or in a prime-boost combination with Baculovirus-expressed gD 
also resulted in accelerated clearance of challenge virus from lungs (Ruitenberg, Walker, et al., 
2000; Ruitenberg et al., 1999a). Inoculation of gD DNA resulted a lowered prevalence of 
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abortion in mice (Walker et al., 2000). Using truncated EHV-1 gD expressed in the yeast Pichia 
pastoris introduced a strong protective responses in mice (Ruitenberg, Gilkerson, Wellington, 
Love, & Whalley, 2001). 
Figure 3.1 EHV-1 vs HSV-1 amino acid alignment and 3D comparison. 
Antibody response induced by EHV-1 gD subunit vaccine was similar to the response 
induced by inactivated whole EHV-1 vaccine (Foote et al, 2006). Injection with DNA vaccine 
encoding EHV-1 gD elicited both humoral and cell-mediated immune responses in a murine 
model of EHV-1 infection (Walid Azab & Osterriedera, 2011; Ruitenberg, Walker, et al., 2000; 
Ruitenberg et al., 1999a, 1999b). Moreover, glycoprotein D from EHV, HSV and BHV has been 
tested in many vaccination studies (N. A. Fuentealba et al., 2014; Mackenzie-Dyck et al., 2014; 
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Ruitenberg, Love, et al., 2000; Walker et al., 2000; Weerasinghe et al., 2006; P. Zhang et al., 
2014). Here, we cloned EHV-1 gD as a virus-vectored vaccine by using the HSV-1 VC2 vector. 
HSV has many non-essential genes and can stably carry large fragments of foreign DNA. 
This genetic flexibility is ideal for the expression of antigens specific to other pathogens (Kaur et 
al., 2007; Watanabe et al., 2007). HSV-1 VC2 mutant virus contains the gK∆31-68 (37aa) 
deletion and a deletion of amino-terminal 19 amino acids of UL20. Intranasal or intramuscular 
injection of mice with 10
7
 VC2 PFU did not cause any significant clinical disease in mice
(Stanfield et al., 2014). Previous experiments in our lab found that VC2 virus can serve as an 
efficient vaccine against both HSV-1 and HSV-2 infections, as well as a safe vector for the 
production of vaccines against other viral and bacterial pathogens (Stanfield et al., 2014). Here, 
we cloned EHV-1 gD sequence into HSV-1 VC2 and constructed a new mutant virus-vectored 
vaccine expressing EHV-1 gD, which was used to test the immune responses in mice. 
3.2 Materials and Methods 
This work has been approved by Louisiana State University Inter-Institutional Biological 
and Recombinant DNA Safety Committee (IBRSDC reference number: 00615) and Institutional 
Animal Care and Use Committee (IACUC reference number: 15-019). 
Virus and cells 
EHV-1 virus was isolated from the placenta of a thoroughbred horse in 2008 and provided 
by Dr. Roy from Louisiana Animal Disease Diagnostic Laboratory (LADDL). 
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Vero cell (African green monkey kidney cell) and NBL-6 cell (Equine dermal cell) were 
both purchased from ATCC and used in the experiments. 
Figure 3.2 Schematic of the construction of VC2. (A) The top line represents the prototypic 
arrangement of the HSV-1 genome, with the unique long (UL) and unique short (US) regions 
flanked by the terminal repeat (TR) and internal repeat (IR) regions. Shown below are the 
expanded genomic regions, which encompass the open reading frames of UL20 and glycoprotein 
K. In black are the approximate deletions within their respective genes. (B) A graphical depiction 
of the gK UL20 complex interacting with gB. Areas between the black lines on the graphical 
depiction represent the approximate location of the deletion in their respective genes (Stanfield et 
al., 2014). 
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HSV-1 VC2 was constructed previously and was proven to be an efficient vaccine against 
lethal HSV-1 and HSV-2 in mice (Stanfield et al., 2014) and guinea pigs (Kousoulas, personal 
communication). The VC2 genome in a bacterial artificial chromosome (BAC) plasmid was 
utilized to construct the new recombinant virus carrying the EHV-1 gD (Figure 3.2). VC2 
contains the gK ∆31-68 deletion and a deletion of UL20 amino-terminal 19 amino acids 
(Stanfield et al., 2014). The VC2 gK mutation prevents the virus from entering into neuronal 
axons of mice and establishing latency in ganglionic neurons, provides a safe vector for the 
production of vaccines against other viral and bacterial pathogens. 
Construction of recombinant virus 
Two-step Red-mediated recombination was used for the construction of the recombinant 
virus HSV-VC2-EHV-1-gD (Figure 3.5) (Tischer, von Einem, Kaufer, & Osterrieder, 2006). The 
EHV-1 gD sequence of 1206 bp was amplified by PCR using primers P1 and P2 (Table 3.1). The 
PCR products were digested with the restriction enzymes Not1 and BamH1 and inserted into the 
vector CMV-14 with a 3X FLAG epitope, resulting in recombinant plasmid CMV-gD. To 
construct CMV-gD-KanR, the KanR gene adjoining I-SceI site was amplified by PCR from 
plasmid pEPkan-S using primers P3 and P4 (Table 3.1), digested with the restriction enzyme 
EcoR1 and inserted into CMV-gD (digested with EcoR1). The CMV-gD-KanR gene was 
amplified by PCR using primers P5 and P6 (Table 3.1) and then cloned into HSV-VC2 to replace 
UL24 (thymidine kinase). The kanamycin cassette was cleavage after expression of I-SceI from 
plasmid pBAD-I-SceI. The inserted EHV-1 gD was verified by capillary DNA sequencing by 
using primers P7 to P12 (Table 3.1). Schematic of new recombinant virus was listed in Figure 
3.3. 
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Figure 3.3 Schematic of the construction of HSV-VC2-EHV-1-gD with 3xFlag (UL23: 
thymidine kinase; UL24: nuclear protein). 
3.3 Results 
The inserted EHV-1 gD was verified by capillary DNA sequencing after Big-Dye 
terminator reactions (Rostamian, Sohrabi, Kavosifard, & Niknam, 2015). There were no 
nucleotide changes between the inserted EHV-gD and NCBI Reference Sequence: NC_001491.2 
(Figure 3.4). 
Figure 3.4 Capillary DNA sequencing results. 
94 
Table 3.1 Oligonucleotide primers used in this study 
Primers Template Sequence 
P1 EHV-1 gD AAGCTTGCGGCCGCGATGTCTACCTTCAAGCTTATG 
P2 EHV-1 gD AAGCTTGGATCCCGGAAGCTGGGTATATTTAAC 
P3 pEPkan-S CTTGGTGAATTCAACTTCCCACAAGGAGAGCATATGAC
ATGGTTGAAGTTCTG-AGGATGACGACGATAAGTAGGG 
P4 pEPkan-S CTTGGTGAATTCCAACCAATTAACCAATTCTGATTAG 
P5 CMV-14 GTGGCGTGAAACTCCCGCACCTCTTCGGCAAGCGCCTT
GTAGAAG-CGCGTCCATGTTGACATTGATTATTGAC 
P6 CMV-14 TTATTGCCGTCATAGCGCGGGTTCCTTCCGGTATTGTCT
CCTTCCGTGTTA-AGGACAGGGAAGGGAGCAGTGG 
P7 EHV-1 gD GGCGTGTACGGTGGGAGGTCTATA 
P8 EHV-1 gD ATGCCAACGTGTGCAACGCCTATA 
P9 EHV-1 gD TTATGAAGCCCAGGCATTCGCAAG 
P10 EHV-1 gD AATTATGCCAACGTGTGCAACGC 
P11 EHV-1 gD CTGGTTCGTCTACGATGGTGGAA 
P12 EHV-1 gD AAGTCTGCACAGAACGGCTTGAC 
Restriction enzyme sites are given in bold letters; underlined sequences indicate the sequences 
annealing to template. 
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Figure 3.5 Insertion of long DNA fragments using the developed mutagenesis protocol. First, a 
universal transfer construct was generated. The transfer construct was amplified by PCR and 
integrated into the target site with a first Red recombination. The cleavage of the I-SceI site in 
vivo and a subsequent second Red recombination resulted in the removal of the positive selection 
markers, leaving behind the sequences of interest. Lines or boxes of identical colors symbolize 
identical sequences. Colored dotted lines indicate single homologous recombination events. soi, 
sequence of interest; psm, positive selection marker; S, I-SceI restriction site; asterisk, unique 
restriction site (Tischer et al., 2006). 
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EHV-1 gD has similar 3D model (Figure 3.1) with HSV-1. They have 100% confidence 
according to Phyre
2
 Protein Homology/analogy Recognition Engine. Domains of EHV-1 gD
align with continuous antigenic sites of HSV-1 gD, suggesting that these two gD polypeptides 
have common structural features (Flowers & O'Callaghan, 1992; N. A. Fuentealba et al., 2014; 
Wellington, Lawrence, Love, & Whalley, 1996) and they might share same epitopes for virus 
neutralizing function. 
VC2 conferred significant protection against either virulent HSV-1(McKrae) or HSV-2(G) 
intravaginal challenge in mice. Also, vaccination with VC2 produced protective humoral and 
cellular immunity that fully protected vaccinated mice against lethal disease. VC2 virus may 
serve as a safe vector for the production of vaccines against other viral and bacterial pathogens. 
Figure 3.6 Plaque morphology of VC2 vs VC2-EHV-gD on Vero and NBL-6 cells 72 hours post 
infection. 
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Figure 3.7 EHV-1 gD expression detected by anti-FLAG antibodies or anti-EHV-1 gD 19-mer 
polyclonal antibodies. Lane 1 and 2: cellular extracts from VC2-EHV-1-gD or VC2 infected 
NBL-6 cells detected by anti-FLAG antibody; lane 3 and 4: cellular extracts from VC2-EHV-1-
gD or VC2 infected Vero cells detected by anti-FLAG antibody; lane 5 and 6: cellular extracts 
from VC2-EHV-1-gD or VC2 infected NBL-6 cells detected by antibodyanti-EHV-1 gD 19-mer 
polyclonal antibodies; lane 7 and 8: cellular extracts from VC2-EHV-1-gD or VC2 infected Vero 
cells detected by anti-EHV-1 gD 19-mer polyclonal antibodies. 
The HSV-VC2-EHV-gD recombinant virus was constructed utilizing the two-step red-
mediated recombination protocol using HSV-VC2 as a vector. The recombinant virus can grow 
both on Vero cell and equine NBL-6 cell lines, which can be tested in murine model and also be 
used as a vectored-virus vaccine against EHV on horses. The mutation affects virus replication 
and the virus produces smaller plaque on Vero and NBL-6 cells compared to original VC2 
(Figure 3.6). Moreover, the virus grows slower on Vero and NBL-6 cells than parental virus VC2 
EHV-1gD protein produced by the mutant virus was detected by anti-FLAG antibodies and 
anti-EHV-1 gD 19-mer polyclonal antibodies after viruses infected Vero and NBL-6 cells 
(Figure 3.7). The infected cell lysis were run on SDS-PAGE (6%) and transferred to the 
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membrane. Expression of gD was detected with mouse anti-FLAG antibody (1/5,000 dilution) 
and anti-EHV-1 gD 19-mer polyclonal antibodies (1/2,000 dilution, kindly provided by Dr. 
Dennis O'Callaghan, Louisiana State University Health Sciences Center, Shreveport, LA). Goat 
anti-mouse or anti-rabbit IgG coupled to peroxidase at 1/5,000 dilutions were used as secondary 
antibodies. Reactive bands were visualized by enhanced chemiluminescence (Figure 3.7). 
Insertion of EHV-gD affects virus replication. VC2-EHV-gD virus replicated not as 
efficiently as the parental virus and the peak virus titer was lower than VC2 on both Vero and 
NBL-6 cell lines (Figure 3.8). 
 
 
 
 
Figure 3.8 Growth curve representative of the replication kinetics of VC2 vs VC2-EHV-gD at 
both high (5) and low (0.1) MOI on both Vero and NBL-6 cells. 
Herpesvirus latency confers a surprising benefit to the host. Mice latently infected with 
either murine γ-herpesvirus 68 or murine cytomegalovirus, are resistant to infection with the 
bacterial pathogens Listeria monocytogenes and Yersinia pestis. Latency-induced protection is 
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not antigen specific but involves prolonged production of the antiviral cytokine interferon-γ and 
systemic activation of macrophages. Latency thereby upregulates the basal activation state of 
innate immunity against subsequent infections (Yanase et al., 2014). 
We hypothesize that HSV-VC2 in the mice or horses may stimulate the humoral and cellular 
immune response to environmental antigens through cytokine secretion. Moreover, embedded 
EHV-gD will excite the specific immune response to combat EHV infection. 
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CHAPTER 4: TESTING OF THE VC2-EHV-GD VACCINE IN THE EHV-1 MOUSE 
MODEL 
4.1 Introduction 
EHV-1 infection involves a local immune response at the primary site of replication as well 
as a systemic immune response which consists of antibody, cytokine and cellular components. 
First time EHV-1 infection induced a fully protective immunity against re-infection lasting 4 to 8 
months (Trapp et al., 2005), although some reports demonstrate shorter periods of immunity 
lasting <3 months. EHV-1 invades the host mostly via mucosal epithelium. The equine lung 
surface has been estimated to total around 2000 m² compared to around 400 m² in humans. EHV-
1 is a persistent virus. The acute clinical signs resolve after a few weeks, but EHV-1 establishes a 
persistent infection with chronic reactivations. A strong mucosal immune response is needed to 
prevent EHV-1 infection before it invades into cells and tissue (S. B. Hussey et al., 2006; Soboll 
Hussey, Ashton, Quintana, Van de Walle, et al., 2014; Wilsterman et al., 2011). Both humoral 
and cellular immune responses are important in protection and recovery from EHV-1 infection. 
Macrophages and lymphocytes are dominant in normal lungs. After EHV-1 infection, 
neutrophils recruits to the tissue inflammation caused by infection, so the percentage of 
neutrophils increases, macrophages and lymphocytes decreases in a few days (Kydd et al., 1996; 
Slater et al., 2006). During the 3 weeks after EHV-1 infection, bronchoalveolar CD8+ T 
lymphocytes increase significantly and show a cytotoxic activity against EHV-1 infected cells. 
Edington et al has also detected Equine type 1 interferon (IFNα/β) in nasal secretions and serum 
of ponies during the first two weeks after experimental infection with EHV-1 (Edington et al., 
1989; D. J. Smith et al., 2001). IFNα/β has variety of immune-modulatory activities and 
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stimulates both innate (e.g. enhancement of natural killer activity) and adaptive immunity (e.g. 
promotion of Th1 response). The secretion of such IFN correlated with the duration of EHV-1 
shedding, which could be an indicator of EHV-1 replication and epithelium damage (Edington et 
al., 1989; Siedek, Whelan, Edington, & Hamblin, 1999). 
Adaptive immune responses to EHV-1 are believed to be initiated in NALT (nasal 
associated lymphoid tissue) and MALT (mucosal associated lymphoid tissue). Kydd et al. 
detected EHV-1 and viral antigens in the retropharyngeal and bronchial lymph nodes as early as 
12h after infection with EHV-1 (Kydd et al., 1994). Natural immunity to EHV-1 is short-lived. 
Complement fixing (CF) and virus neutralizing (VN) antibodies appear within 2 weeks after 
infection with EHV-1 and IgGa, IgGb, IgGc, IgG(T) and IgM antibody serotypes can be detected 
(Hannant et al., 1993; K. C. Smith et al., 1993). However, CF antibodies are short lived and do 
not last more than 3 months, whereas VN antibodies are more durable and usually last more than 
1 year. Virus specific IgA with virus neutralizing activity is dominated in the local mucosal 
humoral response. The mucosal humoral immune response reduced virus shedding induced by 
subsequent infection with EHV-1 a few weeks after the initial infection (Breathnach et al., 2001; 
Holmes et al., 2006). EHV-1 specific immune responses also take place in the draining lymph 
nodes of the respiratory tract after EHV-1 infected subepithelial cells, leucocytes, and spread in 
the host through the blood and lymphatic vessels. The presence of VN antibody prior to EHV-1 
infection reduced the amount and duration of nasopharyngeal virus shedding (Hannant et al., 
1993; Kydd et al., 2003). Although virus neutralizing antibody specific for EHV-1 in serum can 
be associated with a reduction in the amount and duration of virus shed, there are no significant 
effects on cell-associated viremia because EHV-1 viruses become intracellular soon after landing 
on the respiratory mucosal surface and killing of cell associated virus is the major function of 
107 
cytotoxic T lymphocytes (CTL) (G. Allen, Yeargan, Costa, & Cross, 1995; G. P. Allen et al., 
2008; G. P. Allen et al., 2004; Soboll et al., 2003). However, a previous study indicated that 
virus neutralizing antibody stimulated by commercial vaccination did reduce the cell-associated 
viremia but the mechanism is unknown (Goehring, Wagner, et al., 2010). 
There are two main subsets of T lymphocytes, distinguished by the presence of cell surface 
molecules known as CD4+ and CD8+. CD4 lymphocytes are also known as T helper cells, and 
they are the most prolific cytokine producers. This subset can be further subdivided into Th1 and 
Th2, and the cytokines they produce are known as Th1-type cytokines and Th2-type cytokines 
(Garcia-Pelayo, Bachy, Kaveh, & Hogarth, 2015; Tripp, Jones, Anderson, & Brown, 2000). 
Th1-type cytokines tend to produce the proinflammatory responses responsible for killing 
intracellular pathogens and IFN-γ is the main Th1 cytokine. Excessive proinflammatory 
responses can lead to uncontrolled tissue damage, so there is a mechanism to counteract this. The 
Th2-type cytokines include interleukins 4, 5, 13, and also interleukin-10, which introduce an 
anti-inflammatory response. In excess, Th2 responses will counteract the Th1 mediated cellular 
response (Hochreiter, Ferreira, Thalhamer, & Hammerl, 2003). The body should produce a 
balanced Th1 and Th2 response to combat the pathogen challenge. 
Virus-specific cell-mediated responses are important components of immunity against 
herpesviruses. IFN-γ synthesis is one of the most widely used markers of cell mediated immunity 
(CMI) to measure responses to herpesviruses in humans and it has now been applied to horses 
(Luce et al., 2007; Nugent & Paillot, 2009; R. Paillot et al., 2005; R. Paillot et al., 2007; R. 
Paillot et al., 2006; R. Paillot et al., 2008). IFN-γ promotes cell-mediated immune response by 
increasing viral peptides presentation by APC and promoting the development of T helper 1 (Th1) 
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lymphocytes. IFN-γ up-regulates differentiation and activity of TH1 cells and is a key factor in 
the development of cellular response involving cytotoxic T lymphocytes (CTL), which leads to 
the destruction of virus infected cells. Moreover, IFN-γ is an important activator of macrophages 
and inducer of Class I major histocompatibility complex (MHC) molecule expression. IFN-γ is 
produced predominantly by natural killer (NK) and natural killer T (NKT) cells as part of the 
innate immune response, and by CD4 Th1 and CD8 cytotoxic T lymphocyte (CTL) effector T 
cells once antigen-specific immunity develops. Infection elicits the production of large amounts 
of IFN-γ by NK cells, and this secreted IFN-γ is crucial in controlling some infections before T 
cells have been activated to produce this cytokine. The expression of both MHC class I and 
MHC class II molecules is regulated by cytokines, in particular interferons, released in the course 
of immune responses. IFN-γ increases the expression of MHC class I and MHC class II 
molecules, and can induce the expression of MHC class II molecules on certain cell types that do 
not normally express them. IFN-γ also enhance the antigen presenting function of MHC class I 
molecules by inducing the expression of key components of the intracellular machinery that 
enables peptides to be loaded onto the MHC molecules. MHC class I and MHC class II 
molecules have a distinct distribution among cells that reflects the different effector functions of 
the T cells that recognize them. MHC class I molecules present peptides from pathogens, 
commonly viruses, to CD8 cytotoxic T cells, which are specialized to kill any cell that they 
specifically recognize. 
Tumor necrosis factor (TNF or TNF-α) is an important cytokine that triggers local 
containment of infections. Inflammatory mediators also stimulate endothelial cells to express 
proteins that trigger blood clotting in the local small vessels, occluding them and cutting off 
blood flow. This can be important in preventing the pathogen from entering the bloodstream and 
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spreading through the blood to organs all over the body. Instead, the fluid that has leaked into the 
tissue in the early phases of carries the pathogen enclosed in phagocytic cells, especially 
dendritic cells, via the lymph to the regional lymph nodes, where an adaptive immune response 
can be initiated. The importance of TNF-α in the containment of local infection is illustrated by 
experiments in which rabbits are infected locally with a bacterium. Normally, the infection will 
be contained at the site of the inoculation; if, however, an injection of anti-TNF-α antibody is 
also given to block the action of TNF-α, the infection spreads via the blood to other organs. 
Current commercial vaccines that contain inactivated virus give only partial clinical and 
virological protection against respiratory infections with EHV-1 because they do not stimulate 
CTLs and therefore do not control the cell-associated viremia which disseminates virus from the 
respiratory tract (Kydd, Townsend, & Hannant, 2006). 
Mouse models of EHV-1 infection have been used to investigate the vaccine potential of 
various EHV-1 immunogens, the effect of antiviral agents on EHV-1 infection and the 
pathogenicity of EHV-1 strain variants and deletion or insertional mutants. Infection of EHV-1 
in the mouse causes respiratory signs – polypnoea and dyspnoea, as well as signs of systemic 
illness and weight lost. The mice become quiet, are dehydrated, have ruffled fur, hunched 
posture, and occasionally mucopurulent conjunctivitis (Frampton et al., 2004; Ma et al., 2012; 
Walker et al., 1999). The lung histopathology in EHV-1-infected mice is similar to that of the 
horse and is characterized by an acute focal alveolitis and bronchiolitis, eosinophilic intranuclear 
inclusion bodies in bronchiolar epithelial cells, focal necrosis of pneumocytes (M. J. Bartels et al., 
1998; T. Bartels et al., 1998). Although the mouse model of EHV-1 infection is not perfect, its 
extensive use has given direction for vaccine strategies. Here, this study was design to study the 
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immune response in mouse model after immunization of a novel viral-vectored vaccine and 
challenged by wild type EHV-1 virus. 
4.2 Materials and Methods 
This work has been approved by Louisiana State University Inter-Institutional Biological 
and Recombinant DNA Safety Committee (IBRSDC reference number: 00615) and Institutional 
Animal Care and Use Committee (IACUC reference number: 15-019). 
Virus and cells 
HSV-1 VC2 was constructed before in BIOMMED and is a bacterial artificial chromosome 
(BAC) plasmid was utilized to construct the new recombinant virus. VC2 contains the gK ∆31-
68 deletion and a deletion of UL20 amino-terminal 19 amino acids. VC2-EHV-1-gD virus was 
constructed using two-step red-mediated recombination system in E. coli SW105 cells as 
described previously(Stanfield et al., 2014). 
EHV-1 virus was isolated from placenta of Thoroughbred horse in 2008 and provided by Dr. 
Roy from Louisiana Animal Disease Diagnostic Laboratory (LADDL). Vero cell (African green 
monkey kidney cell) and RK13 (Rabbit kidney cell) were by LADDL and cultured using DMEM 
with 5% FBS and 1% Promicin. NBL-6 cell (Equine dermal cell) was purchased from ATCC and 
cultured as the instruction. 
Synthetic peptides 
BALB/c mouse MHC-1 and MHC-2 binding prediction peptides were predicted by IEDB T 
Cell Epitope Prediction Tools (http://tools.immuneepitope.org/main/tcell/). The peptides are 
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listed in the following table and synthesized in LSU Protein Core Lab (Table 4.1, Figure 4.1). 
Those peptides (final 1ng in each reaction tube) were applied to stimulate splenocyte from 
different vaccinated or challenged mice in vitro. 
Table 4.1 MHC-1 and MHC-2 of BALB/c mouse binding prediction peptides 
Allele Length Position Peptide 
1 MHC-1 H-2-Dd 12 338-349 KPPKTSKSNSTF 
2 MHC-1 H-2-Ld 10 47-56 FPPPRYNYTI 
3 MHC-2 H2-IEd 15 365-379 GVILYVCLRRKKELK 
Table 4.2 Vaccination design 
Grou
p 
# of mice Vaccine Dose 
1 20 Naïve No vaccination 
2 20 Vetera
®
 EHV
XP
 1/4 0.1 ml primary, secondary, and a third boost 
3 20 HSV-VC2 10
5
 PFU primary, secondary, and a third
boost 
4 20 HSV-VC2-EHV-gD 10
5
 PFU primary, secondary, and a third
boost 
Vetera
®
 EHV
XP
 1/4 (Boehringer Ingelheim Vetmedica) was diluted as 1: 1000 in DMEM and 0.1
ml was used as single dose on mice. 
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Vaccination 
Seven-week old female BALB/c mice were used in this study (60 mice). We had 4 groups 
of 15 each. Each individual mouse was identified with an ear tag. Vaccination schematic was 
described in the table below (Table 4.2). Vaccines were administered in 2 week intervals for 
three times except naïve group. Mice were observed and weighted daily over the course of the 
vaccination period. Blood were collected from the facial vein every other week. Four mice from 
each group were sacrificed at week six after the final vaccination for tissue collection. 
Challenge 
The challenge study included 4 groups of 11 mice that were vaccinated as described in 
Table 4.3. Challenge experiment was designed as described in the Table 4.3 below. Naïve 
animals did not get any vaccines and a commercial vaccine Vetera
®
 EHV
XP
 1/4 (Boehringer
Ingelheim Vetmedica) served as a control group. Mice were challenged intra nasally with a 
totally volume of 20µL 5×10
7
 PFU EHV (10 µL per nostril) five weeks following the final
administration of the vaccine. 
Table 4.3 EHV-1 challenge arrangement 
Vaccination Number of Animals Challenge 
Naïve 11 10
6 
 PFU Wild Type EHV-1
Vetera
®
 EHV
XP
 1/4 11 10
6 
 PFU Wild Type EHV-1
HSV-VC2 11 10
6 
 PFU Wild Type EHV-1
HSV-VC2-EHV-gD 11 10
6 
 PFU Wild Type EHV-1
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Mice were weighted daily over the course of this study and were monitored daily for the 
development of clinical signs such as ruffled fur, labored breathing, crouching or huddling 
behavior, sluggishness and loss of body weight. Previous research has demonstrated that body 
weight loss is an excellent indicator of EHV-1 infection in the mouse (van Woensel, Goovaerts, 
Markx, & Visser, 1995). Three mice from each group were sacrificed after one week for tissue 
collection and histopathological analysis. 
Tissue collection and analysis 
On two weeks after 3
rd
 vaccination and one week post challenge, three mice from each
group were anesthetized by inhalation of 2-3% isoflurane. Maximum volume of blood was 
collected and mice were euthanized by cervical dislocation. Blood were allowed to clot at room 
temperature for at least 30 minutes. Serum was centrifuged, collected and stored at -20
0
C until
use. Spleens were excised from euthanized animals, minced and passed through a 10 mm nylon 
mesh cell strainer in RPMI 1460 with 10% heat-inactivated fetal bovine serum (HI-FBS). Cell 
suspensions were pelleted by centrifugation at 400×g for 7 minutes and cell concentration was 
adjusted to 10
7
cell/ml for FACS analysis. The lung tissues from all four groups after challenge
were collected and stored at -80
0
C for EHV-1 Real-time PCR test.
Serum neutralization 
Collected serum was used to neutralize 50 µL of stock EHV-1 containing approximately 
100 PFU. After the sera were heated to 56
0
C for 1 h to inactivate complement, samples were
then diluted 1:10 in complete DMEM containing 10% heat inactivated FBS, 50 µL each. Fifty 
microliter of virus dilute was added to each dilution of serum to a total volume of 100 µL. 
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Addition of virus made serum dilutions to 1:20. Serum virus mixtures were placed on a rocker at 
room temperature for 1 hour and titrated on NBL-6 cell monolayers. 
FITC flow cytometry analysis on mice sera 
RK13 were infected with EHV-1 and were harvested by using 1mM EDTA in PBS. 
Fixation/permeabilization solution was then added to the cells. Mouse sera (1:20) from different 
groups were mixed with cells after two times washes and incubated for 30 min at 37
0
C. Goat
anti-mouse conjugate (FITC, 5µl) were added to the suspension and incubated for another 30 
min at 37
0
C. The cells were washed twice by adding 3 ml buffer (1% HI FBS in PBS). BD
Fixative solution was applied to the cells and cells were kept at 4
0
C till flow cytometry analysis.
Antibody subclass determination 
To determine the antigen specific antibody isotypes, 96-well plates were coated with 50 µl 
of EHV-1 infected cell lysate (20µl/ml), then sera from four groups were diluted at 1:100 and 
tested in duplicate. To detect mouse IgG1, IgG2a, IgG2b, IgG3, IgA and IgM isotypes, anti-
mouse Ig subclass-specific HRP-conjugated secondary antibodies (abcam®, 1:10,000 dilution) 
were used. The ratio of IgG2a and IgG1 was calculated by dividing OD values for IgG2a by OD 
values for IgG1 (Cribbs et al., 2003). 
Lymphocytes polychromatic flow cytometry and analysis 
Spleens were excised from euthanized animals, minced and passed through a 10 mm nylon 
mesh cell strainer (Fisher Scientific) in RPMI 1640 medium with 10% heat-inactivated fetal 
bovine serum (HI-FSB) and 1% Primocin. Cell suspensions were then pelleted by centrifugation 
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at 400×g for 7 minutes at 4
0
C. Five milliliter ACK (Ammonium-Chloride-Potassium) Lysing
Buffer was added to the cells. The cells were suspended and kept in room temperature for 7 
minutes, and then the volumes were adjusted to total 25 ml with RPMI 1640 medium. The cell 
concentration was adjusted to 10
7
cell/ml after washed by RPMI 1640 medium.
Figure 4.1 Protein alignment analysis between EHV-1 and HSV-1. 1, 2, 3: peptides used in the 
lymphocytes stimulation test. 
Three different peptides (1ng), 3 µl Golgi-Plus and 100 µl of 10
7
cell/ml splenocyte
suspension were gently mixed. Then the mixtures were incubated at 37
0
C and the splenocytes
were stimulated for 6 hours. Cells were then stained with monoclonal rat anti-mouse CD3 
antibody conjugated to PerCP-Cy™5.5 (BD Biosciences), monoclonal rat anti-mouse CD4 
antibody conjugated to PE (BD Biosciences), rat anti-mouse CD8a antibody conjugated to FITC 
(BD Biosciences), monoclonal rat anti-mouse IFN-γ antibody conjugated to APC (BD 
2
1 3
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Biosciences) and rat anti-mouse TNF antibody conjugated to BV510 (BD Biosciences). FACS 
was assessed using an Accuri C6 personal flow cytometer. The data were analyzed using FlowJo 
software (v10.1r1, FlowJo Enterprise) (Figure 4.10). 
Real-time PCR 
Lung tissues were obtained from all four groups one week after EHV-1 challenge. DNA 
from lungs was extracted using the Qiagen DNeasy Blood& Tissue Kit as the manufacturer’s 
protocol. The eluted DNA was quantified using Nanodrop 1000 spectrophotometer. Equal 
amounts of DNA from each sample were used to perform real-time PCR on Cepheid™ 
SmartCycler™ Real-Time Thermal Cycler. The following primer/probe combinations were used 
to detect EHV-1: 1) EHV1-29f (ATCTGGCCGGGCTTCAAC); 2) EHV1-82r 
(GGTCACCCACCTCGAACGT); 3) EHV1NNP (ATCCGTCGACTACTCG) (Leutenegger et 
al., 2008). 
4.3 Results 
Previous experiments indicated that the VC2 virus did not produce significant clinical 
disease symptoms in mice (Stanfield et al., 2014). No clinical disease symptoms were noted 
throughout the vaccination period (8 weeks) in all treatment groups. There was no significant 
difference on the weight gain during the vaccination period among the groups (Figure 4.2). 
The mice of all groups started to lose weight after challenge with 106 PFU Wild Type EHV-
1, although no clinical symptoms (no fur ruffling, no heavy breath) were observed during 6 
weeks post challenge. No mice died during the challenge experiment in all treatments. 
Pathogenesis of this particular clinical isolate might not strong enough to kill the mice. The 
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unvaccinated group gained weight back slower than other three groups. Mice weight in 
unvaccinated group was significantly less than other groups from day 5 to day 13 and at day 23 
(Figure 4.3). 
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Figure 4.2 Mice weight change during three vaccinations in Vetera/VC2/VC2-EHV-
gD/Unvaccinated groups. No clinical disease symptoms were noted throughout all the three 
vaccinations period. No significant difference on the weight gain among all the groups after the 
third vaccination. 
Antisera from five groups of mice were individually tested at 1:20 dilution. Boosted 
vaccinations increased serum neutralization abilities significantly. Vetera, VC2 and VC2-EHV-
gD groups have significantly higher virus neutralization activities than Unvaccinated group after 
first immunization (Figure 4.4). Vetera and VC2-EHV-gD groups have similar virus 
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neutralization activities during the whole vaccination period. Vaccination of VC2-EHV-gD 
increased virus neutralizing activities (33.6%) in mice after three vaccinations, which was similar 
to commercial whole virus vaccine group (32.6%) and both were significantly higher than 
Unvaccinated group all the time (p<0.01 or p<0.001) and VC2 group at week 8 (p<0.01). VC2 
group also neutralized 65.5 % of viruses after three vaccinations and provided a partial 
protection against EHV-1. 
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Figure 4.3 Mice weight change after challenge with EHV-1 clinical isolate in Vetera/VC2/VC2-
EHV-gD/Unvaccinated groups. Statistics analysis on VC2-EHV-gD vs Unvaccinated: Day 7 *, 
Day 9**, Day 11*, Day23**, Day 27*, Day 31* (One-way ANOVA followed by Newman-
Keuls Multiple Comparison Test *p<0.05, **p<0.01). 
119 
EHV-1 Neutralization
0 2 4 8
0
50
100
Vetera
VC2
VC2-EHV-gD
***
Unvaccinated
******
*
**
*
***
***
**
Weeks after first immunizaion
P
e
rc
e
n
t 
P
F
U
Figure 4.4 Serum neutralization of EHV-1 at a 1:20 dilution of sera from Vetera/VC2/VC2-
EHV-gD/Unvaccinated mice (One-way ANOVA followed by Newman-Keuls Multiple 
Comparison Test *p<0.05, **p<0.01, ***p<0.001). 
VC2-EHV-gD group showed strong antigen specific signals on FITC flow cytometry test 
after vaccinations (Figure 4.5) and the specific anti-EHV-1 signal was significantly high than 
Vetera group (p<0.01) and other two groups (p<0.001). Similar results were also seen on the 
microscopy pictures that VC2-EHV-gD group had the strongest signal (Figure 4.6). EHV-1 
specific IgG antibody signals in the sera from all the groups increased after EHV-1 
challenge.VC2-EHV-gD group was still the strongest group (Figure 4.5), which was also 
observed on the microscopy pictures (Figure 4.7). 
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Figure 4.5 FITC flow cytometry test on mice sera (1:20) from Vetera/VC2/VC2-EHV-
gD/Unvaccinated mice before and after challenge (one-way ANOVA followed by Newman-
Keuls Multiple Comparison Test *p<0.05, **p<0.01, ***p<0.001). 
Table 4.3 Ratio of IgG2a/IgG1 of mice sera in four groups 
Before challenge After challenge 
Vetera 0.65 2.51 
VC2 0.84 3.97 
VC2-EHV-gD 0.43 0.54 
Unvaccinated 1.62 21.00 
Any ratio >1 is associated with Th1 response and any ratio <1 is associated with Th2 response. 
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Figure 4.6 FITC microscopy on mice sera (1:20) from Vetera/VC2/VC2-EHV-gD/Unvaccinated 
mice before challenge. 
Figure 4.7 FITC microscopy on mice sera (1:20) from Vetera/VC2/VC2-EHV-gD/Unvaccinated 
mice after challenge. 
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Figure 4.8 In vitro analysis of humoral immune response. Colorimetric ELISA based on analysis 
of EHV-1 reactive polyclonal IgG Subclass at a 1:100 dilution of sera from Vetera/VC2/VC2-
EHV-gD/Unvaccinated mice produced 8 weeks after first vaccination and 1 week after challenge. 
Statistical comparison conducted using one-way ANOVA followed by Newman-Keuls Multiple 
Comparison Test (*p<0.05, **p<0.01, ***p<0.001). 
IgG1 in mice of VC2-EHV-gD group were significantly higher than other groups after 
three vaccinations and after challenge (Figure 4.8, p<0.001). IgG2a in VC2-EHV-gD group was 
also was significantly higher than other groups before three vaccination (Figure 4.8, p<0.001), 
but no significant difference after EHV-1 challenge. Significantly more IgG2b level was 
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produced in VC2-EHV-gD group than other groups (p<0.05) after three vaccination. It’s 
interesting that IgM in Vetera group was significantly high than other groups before and after 
challenge (Figure 4.9, p<0.01 or P<0.05). No IgG3 or IgA were detected at the 1:100 dilution of 
sera from all treatment groups (date no shown). 
Figure 4.9 In vitro analysis of humoral immune response. Colorimetric ELISA based on analysis 
of EHV-1 reactive polyclonal IgG2b and IgM at a 1:100 dilution of sera from Vetera/VC2/VC2-
EHV-gD/Unvaccinated mice produced 8 weeks after first vaccination and 1 week after challenge. 
Statistical comparison conducted using one-way ANOVA followed by Newman-Keuls Multiple 
Comparison Test (*p<0.05, **p<0.01, ***p<0.001). 
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Figure 4.10 Cell cytometry FACS gating. Cells were first analyzed for their internal and surface 
granular in FCS/SSC, then analyzed for SSC/CD3
+
 (PerCP-Cy™5.5), CD8a+/CD4+ (FITC/PE),
IFN-γ+/CD4+ (APC/PE), TNF+/CD4+ (BV510/PE), IFN-γ+/CD4+ (APC/FITC), TNF+/CD4+
(BV510/FITC). 
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Figure 4.11 In vitro analysis of cellular immune response. Mouse splenocytes CD4
+
 and CD8
+
 T
cells from Vetera/VC2/VC2-EHV-gD/Unvaccinated groups after three vaccinations stimulated 
by EHV-1 gD peptides (Table 4.1). 
To test for the generation of EHV-1 specific cellular immune responses, a surface and 
intercellular labeling assay was utilized to detect IFN-γ and TNF synthesized by CD4+ and CD8+
T cells in the presence of specific peptides (Table 4.11 and 4.12) predicted MHC-1 or MHC-2 
epitopes (Figure 4.1). All 3 peptides stimulated more IFN-γ producing CD4+ in VC2 and VC2-
EHV-gD groups than Vetera and control groups after EHV-1 challenge. There was more IFN-γ 
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producing CD8
+
 in VC2-EHV-gD group stimulated by peptide 1 or 3 after three vaccinations
(Figure 4.11). Also peptide 3 stimulated more IFN-γ producing CD8+ in Vetera group (Figure
4.11). Moreover, all 3 peptides stimulated more IFN-γ producing CD8+ in VC2-EHV-gD group
after EHV-1 challenge. 
Figure 4.12 In vitro analysis of cellular immune response. Mouse splenocytes CD4
+
 and CD8
+
 T
cells from EHV-1 challenged mice of Vetera/VC2/VC2-EHV-gD/Unvaccinated groups 
stimulated by EHV-1 gD peptides (Table 4.1). 
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The peptides stimulated cellular immune response after three vaccination and post 
challenge. There was more TNF producing CD8
+
 in VC2-EHV-gD group stimulated by all
peptides (1, 2 and 3) one week post challenge (Figure 4.12). 
Table 4.4 Real-time PCR on lung tissue of different groups one week after challenge 
Group Tag number Results Ct value 
Vetera 626 NEG 0 
627 NEG 0 
628 NEG 0 
VC2 656 NEG 0 
657 POS 37.19 
658 NEG 0 
VC2-EHV-gD 686 NEG 0 
687 NEG 0 
688 NEG 0 
Unvaccinated 696 POS 34.16 
697 NEG 0 
698 NEG 0 
Real-time PCR was performed on lung tissue after challenge. There was no viral DNA 
detected for either Vetera or VC2-EHV-gD groups. However, one out of three mice in VC2 and 
Unvaccinated groups were detected positive (Table 4.4). 
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4.4 Discussion 
Vaccination of VC2-EHV-gD increased virus neutralizing activities (33.6%) in mice after 
three vaccinations and was similar to commercial whole virus vaccine group (32.6%). Both were 
very significant higher than unvaccinated group (p<0.001). Domains of EHV-1 gD align with 
continuous antigenic sites of HSV-1 gD, suggesting that these two gD polypeptides have 
common structural features (Flowers & O'Callaghan, 1992; N. Fuentealba et al., 2014; N. A. 
Fuentealba et al., 2014; Wellington, Lawrence, et al., 1996). So VC2 group had 65.5% of virus 
neutralizing activities and significant higher than unvaccinated group (p<0.05), provided partial 
protection against EHV-1 (Figure 4.4). VC2-EHV-gD virus stimulated strong virus neutralizing 
activity, which was similar to commercial whole killed virus. Flow cytometry test on mice sera 
revealed that VC2-EHV-gD virus stimulated significantly high specific anti-EHV-1 IgG (Figure 
4.5, p<0.001) antibody. This active humoral immune response introduced by VC2-EHV-gD 
benefited the mice to combat EHV-1 challenge. It had been report that intranasal or 
intramuscular immunization with EHV-1 gD produced antigen specific IgG in serum before 
challenge and provided complete or partially protection in mice and horses (Flowers & 
O'Callaghan, 1992; Foote et al., 2005; N. Fuentealba et al., 2014; N. A. Fuentealba et al., 2014; 
Love, Bell, & Whalley, 1992; Ruitenberg et al., 2001; Ruitenberg, Love, et al., 2000; Ruitenberg 
et al., 1999a; Weerasinghe et al., 2006). 
IgM is a very highly cross-reactive and effective neutralizing agent in the early stages of 
disease. The mean serum Ig levels found for 6-month-old C57BL/6 mice were 0.22 mg/ml for 
IgM, 0.28 mg/ml for IgG1, 0.7 mg/ml for IgG2a, 1.22 mg/ml for IgG2b, 0.18 mg/ml for IgG3 
and 0.075 mg/ml for IgA (Klein-Schneegans, Kuntz, Trembleau, Fonteneau, & Loor, 1990). 
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Mice in Vetera group produced significantly high specific anti-EHV-1 IgM level than other 
groups before and after challenge (Figure 4.9, p<0.05 or p<0.01), which might contribute to virus 
neutralizing activities to the same level as VC2-EHV-gD group (Figure 4.4), although specific 
anti-EHV-1 IgG was significantly lower than VC2-EHV-gD group (Figure 4.5, p<0.01). IgM 
antibodies are the first antibodies produced after an infection and are usually replaced with 
higher affinity IgG antibodies by isotype switching as the immune response progresses (Bego et 
al., 2008), so Vetera group might only have short period of virus neutralizing activities. 
Moreover, IgG2a and IgG1 immunoglobulin isotypes as markers for Th1 and Th2 
response (Ebrahimpoor, Pakzad, & Ajdary, 2013; Koyama & Ito, 2001; Song et al., 2014), were 
investigated in mice before and after EHV-1 challenge. VC2-EHV-gD vaccinated mice 
developed highest IgG1 response before and after challenge. This confirms that Th2 responses 
are strong in this group. In comparison, mice in other groups developed lower levels of IgG1 
(Figure 4.8). VC2-EHV-gD vaccinated mice also developed highest IgG2a response before 
challenge. Thus, mice in VC2-EHV-gD group had balanced expression of IgG1 and IgG2a. And 
a well balanced Th1 and Th2 response is suited to the immune challenge (Berger, 2000). 
The subclass of Ig that is induced after immunization or challenge is an indirect measure 
of the relative contribution of Th2-type cytokines versus Th1-type cytokines. The production of 
IgG1-type antibodies is primarily induced by Th2-type cytokines, whereas production of IgG2a-
type antibodies reflects the involvement of Th1-type cytokines (Yadav & Khuller, 2001). Any 
ratio of IgG2a/IgG1 >1 is associated with a Th1 response and any ratio <1 is associated with a 
Th2 response (Visciano, Tagliamonte, Tornesello, Buonaguro, & Buonaguro, 2012). VC2-EHV-
gD group had Th2 response (ratio of IgG2a/IgG1 <1, Table 4.3) before and after challenge. 
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Vetera and VC2 had Th2 response before challenge and switched to Th1 response after challenge, 
which indicated that EHV-1 infection was undergoing in these mice that preferred cellular 
activities to eliminate the viruses. Th1 responses have been implicated in most forms of acute 
rejection and graft versus host disease, while Th2 responses have been variably associated with 
either protection or chronic rejection (Berger, 2000). 
Our results showed the new virus-vectored virus introduced significantly stronger antigen 
specific IgG in mice serum comparing the commercial vaccine group (p<0.01) and unvaccinated 
group (p<0.001). VC2-EHV-gD also stimulated strong cellular immune response (IFN-γ and 
TNF). IFN-γ is commonly produced by effector CD8+ T lymphocytes upon recognition of 
specific antigen, and it stimulates CTL activity (Adams et al., 2004; Baird, Bowlin, Hotz, Cohrs, 
& Gilden, 2015; Ghanekar et al., 2001; Mbawuike et al., 1999; McCarthy et al., 2015; Murali-
Krishna, Altman, Suresh, Sourdive, Zajac, & Ahmed, 1998; Murali-Krishna, Altman, Suresh, 
Sourdive, Zajac, Miller, et al., 1998; O'Flaherty et al., 2015; Scheibenbogen et al., 2000; Sun et 
al., 2003). Besides performing numerous immune-regulatory functions, IFN-γ has also been 
reported to have direct antiviral effects. Several studies conducted in mice have demonstrated an 
important role for IFN-γ in immune protection from herpesvirus infections (Cantin, Tanamachi, 
& Openshaw, 1999; Cantin, Tanamachi, Openshaw, Mann, & Clarke, 1999; Mikloska & 
Cunningham, 2001; Milligan & Bernstein, 1997; P. M. Smith, Wolcott, Chervenak, & Jennings, 
1994). Vaccination of VC2-EHV-gD increased the numbers of IFN-γ producing CD8+ cells after
stimulation of peptide 3 (Figure 4.11). IFN-γ is critical for innate and adaptive immunity against 
viral infections and is an important activator of macrophages and inducer of MHC molecule 
expression. Also, virus-specific CD8
+
 T cells generated long-lived protection (Shin & Iwasaki,
2012). MHC class I molecules present peptides from viruses, to CD8 cytotoxic T cells, which are 
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specialized to kill any cell that they specifically recognize. Equine PBMC induced IFN-γ 
production by a significantly higher percentage among post-EHV-1 infection compared to pre-
infection samples after in vitro stimulation of with EHV-1. This response was associated with an 
increase in virus-specific CTL activity, a critical immune effector for the control of EHV-1 
infection and disease. Also, EHV-1 challenge infection of ponies resulted in increased 
production of IFN- γ by virus-specific T lymphocytes (Breathnach et al., 2005). 
Tumor necrosis factor (TNF or TNF-α) is an important cytokine that triggers local 
containment of infections. VC2-EHV-gD vaccine group had more TNF producing CD8
+
 T cells
post challenge comparing to other groups, which was in agreement with previous report showed 
a concurrent upregulation of TNF transcripts post infection in RacL11-infected mice (P. M. 
Smith, Zhang, Grafton, Jennings, & O'Callaghan, 2000). TNF stimulates endothelial cells to 
express proteins that trigger blood clotting in the local small vessels, occluding them and cutting 
off blood flow. This can be important in preventing the pathogen from entering the bloodstream 
and spreading through the blood to organs all over the body, which might be helpful to reduce 
EHV-1 viremia. However, further studies are still needed to determine the specific role played by 
TNF in the pathogenesis of EHV-1 infection. 
Adaptive immune responses are essential to protect against EHV-1 infections (Ruszczyk, 
Cywinska, & Banbura, 2004). VC2-EHV-gD virus stimulated both humoral and cellular immune 
responses. The increase of virus neutralizing activities (post immunization), IFN-γ (post 
immunization and post challenge) and TNF (post challenge) producing T cells were observed in 
the experiment, suggesting that VC2 expressed EHV-gD provide a strong adjuvant effect to 
introduce adaptive immune response and might be sufficient against EHV-1 infection. U.S. Food 
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and Drug Administration (FDA) has approved the Biologics License Application for 
IMLYGIC™ (talimogene laherparepvec), a genetically modified oncolytic viral therapy 
indicated for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in 
patients with melanoma recurrent after initial surgery (http://www.amgen.com/media/news-
releases/2015/10/fda-approves-imlygic-talimogene-laherparepvec-as-first-oncolytic-viral-
therapy-in-the-us/ ). Herpes simplex virus became the first Oncolytic virus for treatment of 
melanoma. VC2, a genetically modified HSV-1, might be used a vector to be applied into other 
animals. Additional studies are needed to assess on horses and also the specific T cell memory 
responses after vaccination. 
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